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ABSTRACT 
The American University in Cairo 
Evaluation of Rapid Low-Cost Colorimetric Methods for 
Diagnosis of Multidrug-resistant Tuberculosis in Limited-
Resource Settings 
BY: Mai M. H. Mansour 
Under the supervision of Dr. Hassan M. E. Azzazy and Dr. Moustafa Abdel Fadeel 
One third of the world’s population is currently infected with tuberculosis (TB), a 
consuming airborne disease whose main causative agent is Mycobacterium 
tuberculosis. The majority of these patients are found in the world’s poorest areas. 
Treatment of TB is a lengthy and demanding process utilizing a cocktail of powerful 
drugs; however, multidrug resistant TB (MDR-TB) strains, defined by resistance to 
both isoniazid (INH) and rifampicin (RIF), are now emerging worldwide and 
threatening disease control efforts. The major problem facing efforts to combat MDR-
TB spread is its early detection. Conventional fairly affordable methods for drug 
resistance detection are based on solid culture and are highly time consuming (3-6 
weeks in addition to initial pathogen culturing). On the other hand, the more rapid 
liquid culture-based automated systems are costly to set up and maintain while the 
very rapid molecular assays (hours to few days) are simply too complex and 
unaffordable and non-sustainable in limited resource settings. The objective of this 
work was to evaluate the performance of two liquid culture-based colorimetric assays 
for detection of drug resistance; nitrate reducate assay (NRA) and colorimetric redox 
indicator (CRI) methods for detection of MDR-TB. The assays were tested on 
mycobacterial isolates from Egyptian patients and their performance was compared 
with microscopic observation drug susceptibility assay (MODS) and the commercial 
automated culture system MGIT 960. Concordance was 96.7% for CRI and 93.3%, at 
almost one-tenth of the MGIT cost, and close to that of MODS without the need for 
an inverted microscope. The NRA format used in this study is more convenient and 
higher in throughput than the initially developed format. Additionally, DNA was 
extracted from the mycobacterial isolates and16S rDNA was amplified and sequenced 
to gain insight on the molecular diversity of Egyptian strains. Moreover, the 
molecular basis of strain resistance was investigated by DNA sequencing of the genes 
most commonly containing resistance conferring mutations. Analysis of the 16S 
rDNA sequencing results confirmed the identity of the samples as mycobacterium 
tuberculosis and suggested possible presence of two different strains. On the other 
hand, the analysis of the resistance related genes found common resistance conferring 
mutations in the MDR samples. 
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1. Background and Review of Literature 
1.1.  Tuberculosis  
Tuberculosis (TB), once known as the “white plague” and “consumption”, is one of 
the oldest known diseases. In addition to plaguing medieval and renaissance Europe, 
TB has been traced back and documented in ancient civilizations including Greek, 
Egyptian, and Pervian. To date TB remains a global health problem and pandemic, 
presenting significant challenges in both diagnosis and treatment  [1]. The air-
transmitted disease is caused primarily by the bacterium, Mycobacterium tuberculosis 
(MTB). TB was declared a global emergency in 1993 by the World Health 
Organization (WHO) and currently affects about one third of the world’s population, 
with 8-9 million new TB cases annually. The estimated death toll in 2010 alone was 
1.1 million among human immunodeficiency virus (HIV)-negative people, in addition 
to another 0.35 million among HIV-infected individuals [2-5]. TB remains a 
particularly alarming problem in sub-Saharan Africa where there are high co-infection 
rates with HIV (50% of TB patients in southern Africa are HIV-positive [6]). Overall 
globally, 13% of TB cases occur among HIV-positive individuals. There is only one 
available vaccine; the Bacillus Calmette–Guérin (BCG), a live attenuated vaccine, 
which has been in use since the 1920s, and whose actual benefits are questionable. It 
has a highly variable efficacy (reportedly 0-80%) and does not prevent occurrence of 
TB infection. It rather protects against severe forms of TB such as miliary TB, 
particularly in infants, thereby preventing only about 5% of deaths that could be 
averted via vaccination [7-11]. Despite the fact that incidence rates of TB have been 
declining over the past decade, TB remains an active global threat. It must also be 
noted that the actual TB burden extends beyond the direct death and has an extensive 
social impact, which is visible in the fact that about 10 million children were 
orphaned because of TB in 2009 [3]. The poorest of countries are typically hit the 
hardest by TB as the low standards of living, overcrowdness and poor healthcare 
facilities are direct causes of high infection rates, particularly in areas with high HIV 
prevalence [12].  Additionally, over the next decade it is estimated that the economic 
consequences of TB will claim $1 to $3 trillion, catastrophic figure for nations whose 
people get by with under $2 daily [13]. Asia and Africa bear the worst of the TB 
impact where they have 55% and 30 % of all TB cases worldwide, respectively 
(Figure 1). Egypt-specific TB statistics are presented in table 1.  Notably, in 2007 
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government expenditure on health in Africa was $34 per capita and in Southeast Asia, 
home to 30% of the world’s poor, it was only $15 per capita.  Moreover, almost 80% 
of all TB cases globally are found in 22 countries known as the high burden countries 
(HBCs) [3, 11, 14-15].  These countries include the 7 countries with the highest 
hunger rates globally, according to the United Nations Food and Agriculture 
Organization (FAO) [16]. Low socioeconomic conditions, undernourishment, and 
poor hygiene conditions aggravate the problems of TB, and great concordance 
between TB incidence rates regions and FAO hunger regions are a demonstration of 
this fact. Furthermore, children constitute about 15-20% of TB cases in endemic 
regions [3]. 
 
1.2.   Mycobacterium  tuberculosis (MTB) 
Mycobacterium tuberculosis (MTB) is a member of the Mycobacterium genus of 
acid-fast bacteria, and was first discovered in 1882 by Robert Koch. MTB organisms 
are intracellular pathogens which are aerobic slow-growing (18-24 hr generation time) 
non-motile rod shaped bacilli, measuring 0.5 x 3 µm. It is the primary TB-causing 
member in the mycobacteria, although a few other members are capable of causing 
tuberculosis. These are known collectively as M. tuberculosis complex (MTBC) and 
include M. bovis (causes TB in cattle), M. bovis BCG (the attenuated strain used in 
vaccines), M. africanum (less pathogenic than MTB, causes TB-like symptoms, found 
mainly in West Africa), and M. canettii (found mainly in Horn of Africa). There is 
also M. microti, which is seldom the culprit in human TB cases but causes the disease 
in voles, in addition to M. caprae and M. pinnipedi, which are causative agents of TB 
in goats and deer, and seals, respectively; however, human infection has been 
demonstrated possible [8, 17-18].  
Mycobacteria are characterized by having peptidoglycan cell walls with 
exceptionally high lipid content, mainly mycolic acid (Figure 2), and thus cannot 
retain any conventional stains such as the basic aniline dye Gram stain. This means 
they cannot be classified as either Gram-positive or Gram-negative. However, they 
can be stained with basic lipid-soluble fuschin dyes as they cannot be decolorized 
with acidified alcohol containing 3% HCl, a property known acid-fastness [1, 7-8, 17-
19].  The exceptional cell wall structure of MTB is a key virulence factor, as this 
hydrophobic cell wall is impermeable to many antibiotics, and contains channels and 
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porins that pump out drugs. Also, this lipid-rich rigid cell wall containing the 
carbohydrate lipoarabinomannan allows MTB to survive within the patients’ 
macrophages that engulf the bacilli [18-21]. 
 
1.3.  Transmission and pathogenesis of tuberculosis   
TB is spread by droplet inhalation and merely 1-3 bacilli suffice for infection if 
inhaled [22]. The outcome of infection can be elimination of the bacilli and infection 
clearance, failure to control the infection and development of active symptomatic TB, 
or control of infection by the immune system without clearance of tubercle bacilli. In 
the latter case the patient is noninfective and exhibits no symptoms, however, he/she 
is bearer of dormant bacilli which may be reactivated if the person’s immunity is 
severely compromised e.g. due to HIV infection or uncontrolled sepsis or diabetes 
mellitus [7, 19]. Typically less than 10% of individuals who become infected with TB 
bacilli will develop an active infection. Depending on degree of immunocompetency, 
this value can reach 30%, and coinfection with HIV makes progression to active TB 
disease 21-34 times more likely, and if active TB is left untreated, fatality is estimated 
to be 50% [8, 14, 22-23].  
When infective droplets containing MTB are inhaled, a portion may be 
eradicated by the mucociliary systems in the airways. The evading bacilli that reach 
the lungs are engulfed by macrophages as an infection containment defense. 
However, MTB possesses an extraordinary ability to persist within the macrophages 
and counteracts their destruction mechanisms. The first line of defense for MTB 
against the destructive environment inside macrophages is the sturdy cell wall. On 
another front, MTB counteracts the acidification process initiated by the 
macrophages, thereby changing the pH within the macrophage from the deadly 4.5-5, 
to a near neutral 6.4. Moreover, the entire metabolic profile of MTB alters so as favor 
survival within the hostile macrophage environment with limited nutrients [7, 18-19]. 
The accumulation of macrophages and T-lymphocytes around the tubercle 
bacilli creates a granuloma in this region. Necrosis then sets in and gradually the 
bacilli are trapped within the characteristic lesions in a microenvironment with low 
oxygen, pH, and nutrients. The bacilli thus minimize all their metabolic functions and 
go into a non-replicative dormant state, and latent TB is established. If the patient 
immune system is not sufficiently strong, or if latent TB is reactivated, the bacilli 
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cannot be contained within the granulomas, which burst open and the bacilli spread. 
They can spread to the alveoli and cause pulmonary TB, or the infected macrophages 
can take the bacilli to other organs causing extrapulmonary TB (20% of all TB cases) 
e.g. lymphatic TB. The clinical symptoms of active TB are rather non specific, they 
include fatigue, night chills and sweats, malaise, progressive weight loss, low-grade 
fever, and coughing in pulmonary TB where sputum is usually tainted with blood [7, 
12, 18-19]. 
 
1.4.  Drug-resistant tuberculosis 
MTB has an intrinsic resistance to a variety of antibiotics by virtue of its exceptional 
cell wall structure which also include multiple efflux mechanisms to counteract drug 
and antibiotics, in addition to -lactamase activity. Additionally, drug resistance of 
TB can either be primary or acquired, table 2 provides definitions for key terms 
related to drug resistance [21, 24], and multiple factors contribute to the development 
of drug resistance in a TB isolate. Resistance to a single drug can be the outcome of a 
spontaneous mutation in the respective resistance-conferring gene, an event which 
occurs in wild MTB strains every 10
6
 to 10
8
 replications. For the two main anti-TB 
drugs isoniazid (INH) and rifampicin (RIF), the rate of  spontaneous resistance-
conferring mutations are 2.56x10
-8
 and 2.25x10
-10 
, respectively [25]. The use of drug 
combinations in TB therapy reduces the likelihood of emergence of resistance, as the 
risk of a stain harboring two resistance mutations is less than 10
-18
 [21]. The primary 
cause of acquired TB drug resistance is prior unsuccessful or incomplete therapy, and 
thus drug resistance is significantly more likely in retreatment patients, who represent 
about 13% of notified TB cases worldwide [21, 26]. 
An issue with global ramifications is the rise of the incidence of drug-
resistance in TB, particularly multidrug-resistant TB (MDR-TB) strains worldwide. 
MDR-TB strains demonstrate resistance to both rifampicin (RIF) and isoniazid (INH), 
the two main drugs of first line anti-TB antibiotics [27-30]. MDR-TB strains currently 
infect about 50 million patients worldwide [7, 31], with almost 500,000 new cases 
annually [32]. MDR-TB cases  account for about 2.9% of all new TB cases worldwide 
[25] with the prevalence of MDR-TB in retreatment cases differing significantly 
between countries (30% to 80% [33]), with the countries of the former Soviet Union 
having a particularly significant increase in incidence of MDR-TB [4]. Figure 3 
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illustrates the global distribution of proportion of MDR-TB cases among notified new 
cases of TB. 85% of the global cases of MDR-TB can be found in 27 HBCs, with 
China and India alone comprising half of the global MDR-TB burden [34]. This 
makes up a combined total of 36 HBCs for TB and MDR-TB [3]. Another alarming 
fact is that an estimated 5-7% of the annual new MDR cases become extended drug-
resistant TB (XDR-TB). XDR-TB strains are additionally resistant to a fluorquinolone 
and at least one of the injectable antibiotics: amikacin, kanamycin, and capreomycin 
[21]. 
Despite presenting a significant challenge, MDR-TB is treatable with second-
line drugs (e.g. fluoroquinolones). However, early diagnosis is crucial for proper 
management of the patient [33, 35]. In 2008, 150,000 lives were lost to MDR-TB, 
mainly because the patients did not receive the required second-line drugs [25]. The 
fact that only about 7% of global  MDR-TB cases are detected is extremely alarming 
[36]. In Egypt, less than 3% of newly diagnosed MTB cases are classified as MDR-
TB, however,  this figures rises to about 38% among retreatment cases [34]. Despite 
the increase in number of MDR-TB cases receiving treatment in 2010, they still 
account for a meager 16% of the notified MDR-TB cases that year. This is not 
surprising when considering that in the majority of countries less than 5% of both new 
and retreatment TB patients were tested for presence of MDR-TB strains [3]. 
 
1.5.  Genome of Mycobacterium tuberculosis 
MTB is noted for genetic homogeneity, and the genome of the reference virulent 
strain H37Rv was sequenced in 1998 and is about 4.4 Mb in size, with a high GC 
content (65.6%), and 4,000 genes [5, 8]. This is currently the only universal control 
available for drug sensitivity testing (DST), as a characterized pathogenic pan-
susceptible strain [37]. The phenotypic and virulence variations observed among 
different MTB strains may be molecularly attributed to polymorphic genomic ‘regions 
of difference’ (RD), which measure about 0.5 kb [5, 8]. Correlation between 
expression levels of RD1 antigens with strain virulence has been demonstrated with 
the BCG vaccination strain, and the deletion of RD1 has been shown to be a key 
factor in the loss of strain pathogenicity [8, 38-39]. Certain RD loci, can also be of 
utility in strain lineage identification, such as MTB deleted region 1 (TbD1) whose 
presence or absence helps define MTB lineages [8]. 
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The currently circulating strains of MTBC are believed to have emerged from 
a common ancestor, M. prototuberculosis, 40,000 years ago in East Africa, then 
spread in concordance with human population motion. Then about 20,000 years ago 
two lineages emerged, one which became exclusive to human infection and the other 
caused animal infections [8, 40]. Currently circulating MTB strains comprise six 
major clades with geographical association. Also, there is strain variability in disease 
development and interaction with host immune system [1, 41-42]. The Beijing strain, 
the most thriving current strain which showed about 500-fold population expansion 
almost 180 year ago, along with the Indo-Oceanic lineage are significantly more 
likely to cause disseminated tuberculosis and meningitis compared to European 
lineage strains. Also, multiple cases of drug resistance were found to be associated 
with strains belonging to W or W-like families, and animal model studies highlight the 
association of W-Beijing strain with high virulence and increased dissemination, and 
early mortality [12, 40-42]. Figure 4 illustrates geographical strain migration. 
 Regarding Egypt, there is no clear data on the predominant circulating strains 
of MTB and the most recent study found, only indicates that there is unexpectedly 
high proportion of Manu lineage strains, but does not provide details of the circulating 
strains [43]. Such information is important not only for epidemiological analysis and 
infection tracing to aid disease control efforts , but also due to the presence of 
evidence that there is some correlation between genotypes and disease progression 
[44]. This is particularly noting that Egypt is expected to have mixed lineages in the 
circulating strains (Figure 4). 
 
1.6. Treatment of tuberculosis 
The availability of effective drugs make TB a manageable disease, however, the cost, 
both monetary and humanitarian, is by no means small. Treatment of TB is a lengthy 
and demanding process. A typical treatment course would last 24-36 weeks using a 
combination of drugs, which is one contribution to noncompliance of patients and 
premature interruption of therapy, leading to relapse and possible emergence of drug 
resistance  [24-25]. The emergence of MDR-TB and XDR-TB along with HIV 
coinfection has compounded the treatment challenges. Treatment of MDR-TB 
requires a minimum of 18-24 months of therapy and has 60-70% success rates and 
mortality rates range from 10-15%, and can cost up to 200 times more than drug-
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sensitive TB [25, 45]. On the scale of a nation’s economy, about $4 billion are needed 
each year to sustain the infrastructure required for treatment of TB patients, which is a 
substantial financial burden on the struggling economies of developing low-income 
countries [13]. However, the use of the WHO directly observed treatment short course 
(DOTS) strategy between 1995 and 2010 resulted in 7 million saved lives and 
successful treatment of 46 million patients [3].  
The first anti-TB to be discovered was streptomycin (SM) in 1944. However, 
due to extensive SM monotherapy, resistance developed rapidly to it [1, 21, 46]. The 
first line anti-TB drugs comprise isoniazid (INH), rifampcin (RIF), pyrazinamide 
(PZA), ethambutol (ETH), and streptomycin (SM), where INH and RIF are the two 
most potent drugs. Table 3 describes these drugs and their actions, while their 
chemical structures are shown in figure 5. INH, the first oral anti-TB drug, was first 
discovered in 1952, and an INH monotherapy is favored for the latent TB treatment 
[1, 45-46]. The discovery of rifamycin compounds in 1957, strengthened the anti-TB 
arsenal with another oral drug; RIF [1, 24]. RIF must always be given in conjunction 
with another potent antimycobacterial as resistance readily emerges to it [26], and 
resistance to rifampicin is sometimes considered a marker for MDR [47]. Table 4 
presents the molecular basis of resistance to first-line drugs. 
The standard treatment regimen for new TB patients is 2 months of INH, 
ETH, RIF, and PZA, followed by 4 months of INH, RIF, and ETH. Drugs are 
administered 5 to 7 times weekly in most regimens. As for retreatment patients, who 
made up 13% of TB notifications in 2007, DST is recommended prior to therapy 
initiation and should be the guide for therapy design [26, 45]. However, if DST is not 
promptly available, the general approach involves treatment duration of about 18-21 
months. This involves use of at least 4 drugs to which are likely to be effective as 
resistance to them is not expected, including an injectable for 7 months followed by a 
minimum of 3 likely effective drugs. Drugs with expected cross-resistance must be 
excluded [25-26]. The need for using the drugs cocktail for TB treatment is the need 
to eliminate tubercle bacilli at different metabolic and growth phases, thereby each 
drug has a different role in treatment [25, 46, 48], as shown in table 3. Figure 6 
illustrates the target of different TB drugs of the different phases of TB in infection. 
In case of intolerance to INH or resistance, 4 month of RIF is an alternative in 
such cases [45]. INH resistance accounts for almost half of all cases of TB drug 
resistance, amounting to almost 7.4% of all resistance cases. Additionally, it was 
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found that monoresistance to INH further aggravates the problem of MDR-TB, as it is 
a primary risk factor for acquired rifampicin (RIF) resistance [25]. The frequency of 
INH resistance in vitro is 1 in 105 -106 bacilli [46]. Isolate susceptibility to both RIF 
and INH makes detection of ETH or SM resistance inconsequential, as treatment 
regimen will not require modification, and DST for these drugs can only be performed 
if specifically relevant to a particular patient treatment [49]. In regions where 
prevalence of INH resistance is more than 10%, for new TB patients,  a 2 month 
intensive treatment phase using INH, RIF, PZA, and ETH followed by a continuation 
phase including ETH, plus INH and RIF. Also, the standard recommendation for 
isoniazid monoresistance, despite uncertainty of effectiveness, is 2 months RIF, ETH, 
and PZA, followed by 8 months RIF and ETH [25]. 
 
1.7.  Diagnosis of tuberculosis infection  
The main strategies for TB diagnosis have not changed much for decades, and 
in most regions with high TB burden.The primary detection methods of active 
infection rely on finding the TB bacilli in patient sputum smears. This is a relatively 
simple, fast, low cost approach that dates back to more than 100 years, however, and 
yet it misses about 30-35% of positive cases [3, 31]. Culture identification is 
recommended for smear negative samples and DST, and chest x-ray may be 
performed sometimes in presence of suggestive clinical symptoms to aid diagnosis 
[3]. The inadequate performance of the current diagnostic strategies is reflected by the 
global detection rate of 62%, falling short of the 2005 goal of 70% set by the World 
Health Assembly, the decision-making entity of the WHO [50]. The magnitude of 
resource limitation for TB diagnosis is demonstrated by the fact that still 8 of the 22 
HBCs lack the WHO recommended 1 microscopy center per 100,000 population [3]. 
Table 5 summarizes the main diagnostic strategies available for TB and their 
limitations. 
 
1.7.1. Phenotypic and biochemical identification  
1.7.1.1.Microscopic examination  
Smear microscopy relies on the examination of sputum smears for acid-fast bacilli 
(AFB) stained using acid-fast Ziehl Neelsen (ZN) stain (primary dye is carbolfuschin) 
(figure 7). For detection of positive samples, a minimum of 300 microscopic fields 
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must be observed, and AFB smear microscopy requires the presence of at least 5,000 
to 10,000 bacilli per mL of sputum, a lower bacillary load would be missed. AFB 
smear microscopy is useful for detection of active TB infection as non-viable bacilli 
with damaged cell walls may lack the acid-fastness upon which the staining is based 
[4, 17, 48, 51-53]. The recommended procedure for use of smear microscopy to detect 
pulmonary TB involves the examination of two sputum smears, and morning 
collection specimens are preferred [3, 11]. 
The detection rates are highly variable ranging from 20-80%. Detection rates 
below 20% are observed in HIV patients, and extrapulmonary TB, and MDR strains 
cannot be detected, and almost 60% of all TB notifications are either smear-negative 
or extrapulmonary cases. Also, AFB smears cannot differentiate MTB from 
nontuberculous mycobacteria (NTMs) with similar looking bacilli, which can pose a 
problem in area where TB is not endemic [3-4, 27, 53]. An estimated minimum 17% 
of new infections are acquired from others who tested smear-negative [24]. One 
approach which is suggested to improve AFB smear sensitivity is sputum 
concentration prior to examination either by passive sedimentation or treatment with 
bleach or ammonium sulphate, followed by centrifugation [11]. 11-26% improvement 
in sensitivity has been reported when the latter method was used [54].  
A number of recent improvements have been developed to enhance the 
performance of smear microscopy. One of which is the use auramine/rhodamine 
fluorescent dyes for staining smears and the use of fluorescence microscopes for 
examination. Despite providing a notable enhancement in sensitivity, throughput, and 
speed of detection, this modification also comes with a significant increase in cost, as 
the stain, the microscopes and their bulbs are expensive. A possible compromise 
between cost and performance advantages of fluorescence microscopy may be 
provided by the newly developed light-emitting diode (LED) microscopes, which are 
cheaper than regular fluorescence microscopes and can emit regular white light as 
well as fluorescence wavelengths.  The use of LED smear microscopy has been 
endorsed by the WHO, and several commercial products for TB diagnosis are now 
available [3, 11, 52, 55]. 
 
1.7.1.2. Immunological assays 
The main utility of immunological assays in TB diagnosis is screening for latent TB 
infection.  One of the oldest and most widely used assays is the tuberculin skin test 
10 
 
(TST), also known as the Mantoux test. This test involves intradermal injection of TB 
purified protein derivative (PPD) and then examining the area of injection after 2-3 
days for induration. TST detects the cell-mediated immune reaction to the infection, 
and the cut off diameter of the induration for a positive reaction depends on the risk 
group to which the patient belongs. False positive results can be observed in 
previously vaccinated or exposed individuals, and cross reaction with other 
mycobacteria, as some antigenic components of PPD are conserved among 
mycobacteria. Also, false negatives are observed in case of immunocompromised 
patients and those with recent active infection [2, 12, 14, 19]. 
Another immunological assay; the interferon gamma release assay (IGRA), 
measures interferon gamma release by T-cells in response to exposure to certain MTB 
antigens. Initially PPD was used and then other proteins with higher specificity to 
MTB came into use instead, which are encoded by genes in the RD1 region of the 
genome e.g. early secreted antigenic target 6 (ESAT-6) [2, 12]. This region is very 
specific to MTB as it is not found in the BCG vaccine strain and most NTMs, and 
IGRAs have demonstrated superior specificity to TST and similar sensitivity [2, 8, 
56]. However, clinical performance of IGRAs is inadequate for detection of 
extrapulmonary TB. Three commercial FDA-approved IGRAs are available; T-SPOT 
TB test (Oxford Immunotech, Abingdon, UK), QuantiFERON-TB Gold (Cellestis 
Ltd, Carnegie, Australia), and the QuantiFERON-TB Gold in tube (Cellestis Ltd, 
Carnegie, Australia). After demonstration of significantly superior performance to 
TST, IGRAs are currently the only available methodology for accurate detection of 
latent TB infection, a critical determination for the success of disease control efforts 
[2, 12, 19, 52, 56-58].  
On a different front, immunological assays are being developed in attempt to 
provide fast, direct, non-invasive diagnosis of TB by detection of relative antigens in 
urine. This could also mean the possibility to develop point-of-care tests which would 
greatly benefit low-income regions with endemic TB. Another important advantage of 
detection of TB antigens is avoiding false results due to modulations of the host 
immune response as is the case with HIV patients when testing for antibodies. 
Additionally such antigens are generally associated with actively replicating 
pathogens and thus allow distinguishing between active and latent TB infections [6, 
50, 59-60]. 
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Lipoarabinomannan (LAM) is a mycobacterial cell wall glycolipid which was 
originally found in patients’ serum, but was later found to be excreted in urine. LAM 
is currently detected using enzyme-linked immunosorbent assay (ELISA) and is 
particularly sensitive in HIV-positive patients and in smear-positive patients. 
Nevertheless, the overall sensitivity and specificity of LAM detection assays are not 
yet adequate for conclusive diagnosis of active TB infection [50, 59-60]. However, 
LAM urine testing combined with smear microscopy can be of value for TB detection 
in areas of high HIV prevalence [6]. In addition to LAM, a number of other urine 
antigens are being investigated. These include MTB ornithine carboamyltransferase, 
phosphoadenosine phosphosulphate reductase, homoserine O-acetyltransferase, and 
MoaA-related protein as markers of active pulmonary TB infection [31, 61]. 
 
1.7.1.3. Culture methods 
The current gold standard for diagnosis of MTB infection is bacterial culture, which is 
very sensitive, however, it is extremely time consuming (typically 3-4 weeks), and 
has substantial infrastructure and biosafety requirements. Solid media include the 
conventional and popular egg-based Lowenstein Jenssen (LJ), and the agar-based 
Middlebrook 7H10, and the newly developed TK medium [4, 18, 48, 52]. LJ cultures 
are highly sensitive and can detect as few as 10-100 bacilli, and figure 8 shows the 
typical colony morphology of MTB grown on them. The TK medium, which has 
comparable sensitivity to LJ, has the advantage of having a colorimetric indicator 
incorporated within it, which indicates the mycobacterial growth even prior to colony 
visualization. However, larger studies are needed for performance validation [17-18, 
58, 62]. Sputum specimens to be cultured are first decontaminated and liquefied using 
N-acetyl-L-cysteine (NALC)-NaOH (2%) treatment, and then planted on the culture 
medium. NALC is a mucolytic agent while the NaOH kills normal flora in the 
sputum. The treatment includes a centrifugation for concentration of bacilli.However, 
overtreatment of the sputum using this approach e.g. using excessive reagent volume 
with respect to the sample volume, can kill almost one third of the mycobacteria in the 
clinical specimen [11, 18, 58]. 
 Conventional culture methods also incorporate subsequent multiple 
biochemical properties allow differentiation of MTB from other mycobacteria. MTB 
has the capacity to reduce niacin and nitrate but yields a negative result with catalase, 
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tellurite, and thiophene-2-carboxylic acid hydrazide (TCH) tests. Additionally, 
identified and differentiated from NTM using media that contains para-nitrobenzoic 
acid (PNB), which inhibits MTB growth  [18, 63]. 
The development of liquid media such as the Middlebrook 7H9 has resulted in 
notable improvement in rate of mycobacterial recovery from primary specimens. 
Greater sensitivity is provided by use liquid media and case detection yield can be up 
to 10% higher than solid media [64]. A decrease of detection time has also been 
provided along with aiding the development of more efficient semi-automated and 
automated commercial detection systems since the 1980s. These include radiometric 
Bactec 460 TB System (BD Diagnostic Systems, MD, USA), and the non-radiometric 
Mycobacterial Growth Indicator Tube (MGIT) 960 system (BD Diagnostic Systems, 
MD, USA). Both systems use Middlebrook 7H9 media supplemented with a growth 
supplement; oleic acid, albumin, dextrose, and catalase (OADC), and a mixture of 
antimicrobial agents; polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and 
azlocillin (PANTA). Notably, the MGIT 960 and other similar systems from different 
suppliers, all show a higher rate of contamination than the older Bactec 460, whose 
production is being discontinued. However, the latter has the major disadvantage of 
radioactive waste generation [11, 58, 65].  Despite high sensitivity, throughput, and 
speed, these automated systems require costly infrastructure setup, maintenance, 
reliable power supply, and have a relatively large footprint, all of which are factors 
hindering their routine use in low-resource settings. Liquid media offer speed and 
higher mycobacterial recovery rates in cultures. However, they are more costly and 
more liable to contamination, in addition to the need for stricter biosafety and staff 
training measures due to risk aerosol formation [14, 17-18, 52, 58]. It is to be noted 
that a contamination rate under 10% in liquid culture is regarded as acceptable [11]. 
Nevertheless, the overall performance advantage of culture using liquid media has 
prompted WHO recommendation of their use in low and middle-income regions [3, 
11]. Table 6 describes the operation principles and performance of notable 
commercial culture methods 
 
1.7.2. Molecular identification methods 
One of the most common targets for bacterial identification, including mycobacteria is 
the highly conserved 16S rRNA gene, and can be utilized for phylogenetic analysis. 
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Sequencing of the 16S rDNA remains the reference method for mycobacterial 
identification, although other options include restriction fragment length 
polymorphism (RFLP) analysis of amplified 16S rDNA regions or probe 
hybridization. The genomic targets for such analysis are primarily in the 5’ section of 
the 16S rRNA gene and amount to about 500 bp in size [66-68]. The 16S rDNA 
contains 9 hypervariable regions (V1-V9) which have the sequence diversity used for 
bacterial speciation [66]. V2 which spans nucleotides 137-242 was found to be useful 
in detecting mycobacterial species and differentiating them [66]. Two hypervariable 
regions were also recognized as particularly valuable for mycobacterial species 
identification and differentiation; region A which spans positions 123 to 273, and 
region B which spans positions 430 to 500. Region A is usually suitable for 
identification of most mycobacteria as unique sequences are exhibited by them in that 
region [67, 69-72].  A minimum of 94.3% similarity between mycobacterial species is 
found in the 16S rDNA [22]. Other target genes for mycobacterial identification 
include the 16S-23S internal transcribed spacer (ITS), and the genes rpoB, gyrB, and 
hsp65 [11, 67-68, 72]. MTB-specific genomic regions make up about 600 kb, about 
half of which have resulted from lateral gene transfer [22]. 
 A large repertoire of molecular techniques, both commercial and in-house, is 
available for MTB identification. The majority of these techniques are amplification-
based e.g. conventional and real-time PCR, strand displacement amplification (SDA), 
followed by electrophoresis detection or probe hybridization. Isothermal amplification 
methods like loop-mediated isothermal amplification (LAMP) are also available. To 
date, no commercial molecular assay has gained FDA approval for detection of MTB 
from extrapulmonary specimens. However, several have been cleared for direct 
detection of MTB in processed sputum samples. Gen-Probe Amplified MTD (Gen-
probe Inc., USA) is FDA-approved for use with both smear-positive and smear-
negative pulmonary specimens. [11, 51, 58]. Table 7 presents the main commercial 
molecular detection assay for MTB detection and their target regions and performance 
parameters.  
A common target for in-house molecular amplification assays for MTB 
identification, is the IS6110 region, however, there is notable variation in sensitivity 
and specificity between different studies [51]. Notably, IS6110 RFLP has the highest 
power of discrimination for strain typing and evaluation of genetic diversity, inspite 
of  its high technical demands [42] Although, molecular assays can shorten detection 
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time to a few hours, their routine use is not always deemed practical, especially in 
low-income regions. This is on account of thehigh cost of equipment set up and 
maintenance, and requirement for highly trained personnel [51, 73].  
 
1.7.3. Other detection approaches 
The quest for efficient strategies detection of TB continues on all fronts and targets 
various disease markers. Rotherham et al. [74] used aptamers to successfully  detect a 
heterodimer of the promising antigenic markers ESAT-6 and 10-kDa culture filtrate 
protein (CFP-10) in TB-positive sputum samples. The detection was done using and 
enzyme-linked oligonucleotide assay (ELONA). The choice of using aptamers, which  
composed of single stranded DNA, is attributed to their higher specificity and lower 
cost of production compared to antibodies (10-50 time cheaper) conventionally used 
for antigen detection.  
 
Baptista et al.[75] resorted to using the increasingly promising gold nanoparticles 
(AuNPs), with their exquisite optophysical properties. The exquisite optical properties 
of AuNPs are attributed to a phenomenon known as surface plasmon resonance (SPR) 
and a closely related phenomenon called plasmon-plasmon interaction. A colloidal 
solution of spherical AuNPs is red, however, when nanoparticles aggregate, 
interaction of locally adjacent AuNPs (plasmon-plasmon interaction) shifts this color 
to blue [75-76]. The group used nanoprobes composed of AuNPs linked to thiol-
modified oligonucleotides for the detection of the DNA of MTBC members, after 
first-round PCR amplification. The simple colorimetric assay is based on resistance of 
AuNPs to salt-induced aggregation upon hybridization of the nanoprobes with the 
complementary target due to formation of dsDNA providing charge stabilization and 
steric hindrance preventing the aggregation of AuNPs. Therefore, following PCR and 
nanoprobe addition, MTBC-positive samples remain red as due to hybridization of the 
nanoprobes with their target, while in the negative samples the AuNPs are allowed to 
aggregate and the color of the solution turns blue [75]. The same group developed the 
assay further to a miniaturized platform that could be used at the “point-of-need”. The 
assay was performed in a 384-well paper microplate (5 µl reaction volume per well) 
thereby enhancing color visibility due the contrast with the white paper background. 
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The result was documented using a smartphone camera and analyzed using a simple 
RGB program anlaysis program on the same device [77]. 
 
1.8. Guidelines for detection of active and latent TB and infections 
The National Institute for Health and Clinical Excellence (NICE) in the United 
Kingdom has put forth recommendations for guidance of detection  efforts for TB in 
2011[78]. These recommendations were based on analysis of a multitude of 
systematic reviews addressing the issue of diagnosis of TB infection. For diagnosis of 
active TB infection a chest x-ray is recommended as the starting point. If the x-ray 
results are suggestive of TB infection, sputum smear microscopy and culture are 
performed (using at least 3 sputum samples). Rapid molecular tests are recommended 
for patients with positive sputum smears in case the test result would cause a 
modification of patient treatment. As for latent TB detection, use of IGRAs is 
recommended for individuals whose Mantoux test is positive [78]. 
 
1.9.  Detection of drug resistance  
The current most commonly used detection method of active TB, sputum microscopy, 
cannot detect drug resistant strains– more advanced methods are needed for DST [3, 
27]. Conventional DST methods have been slow and labor-intensive due to the 
lengthy time required for culturing MTB. Performance of DST is not a routine step 
while testing for TB infection in most countries with high TB burden, but is typically 
done in reaction to the patient’s failure to respond to standard therapy. This means 
that drug resistance and DST would be performed anywhere from 2 to 8 months after 
start of treatment, with no positive effect while enduring all the adverse drug effects 
[24]. Conventional methods include the resistance ratio method, the absolute 
concentration method, and the current gold standard proportion method. All of these 
methods have rather long turn-around time (TAT), where solid media culture methods 
using egg or agar-based media require 3-6weeks. This is in addition to the initial 
pathogen isolation procedures which take 2-6 weeks. More recently, liquid culture-
based methods have been developed which have shorter TAT (albeit still relatively 
long for optimal clinical interventions), but may be significantly more expensive. This 
is a crucial factor in limited-resource countries which typically have the highest TB 
burden [32, 47, 79-82]. The more advanced and expensive liquid media-based 
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methods shorten TAT for DST to 1-2 weeks [83]. Notably, the use of line probe 
assays and automated liquid culture based DST is recommended by WHO [14]. 
Tables 7 and 8 summarize the main features of the phenotypic and genotypic DST 
methods which will be presented in the coming sections. 
 
1.9.1. Conventional DST methods 
1.9.1.1. Phenotypic DST methods 
DST testing can be performed directly on clinical specimen, or indirectly by testing 
pure isolates cultured from clinical specimens. Direct testing of primary clinical 
specimens saves the time needed to first culture MTB from sputum (at least 2 weeks) 
and then perform the DST on the culture. Several commercial assays can be used to 
perform direct DST, however, despite the time disadvantage DST is generally 
performed indirectly so asto avoid the ~15% of failed tests attributed to problems and 
interferences from contaminating bacteria or NTMs in the clinical samples [24, 58]. 
The popular proportion method remains gold standard for DST, almost 50 years after 
its initial development, which can be performed using different solid media including 
the most popular LJ, and Middlebrook 7H10 agar. Medium tubes with and without the 
drugs to be tested are inoculated with 100 µL of the bacterial suspension are 
inoculated per LJ tube with and without the drug to be tested and incubated at 37 ºC. 
After 28 days of incubation the number of colonies in each tube is counted. The ratio 
of number of colonies counted in the drug containing tubes compared to those in the 
drug-free tubes is calculated. If the proportion exceeds 1% (for INH and RIF) or 10% 
for other first line drugs, and second line drugs except para-amino-salicylic acid, the 
isolate is designated resistant. In order to designate an isolate as susceptible, 
incubation must be extended and on the 42
nd
 day if the proportion does not exceed 
1%, the isolate is considered susceptible [47, 51, 84].  
The absolute concentration is based on growing the strains to be tested in 
presence of the drugs at critical concentrations, and the drug-susceptible reference 
strain H37Rv is also grown in parallel for quality control. After 4 weeks of 
incubation, if the drug-free growth control has 100 colonies while the drug-containing 
culture has less than 20 colonies, the isolate is considered susceptible [24]. 
 The  resistance ratio (RR) method, involves culturing the samples and the 
H37Rv strains on solid media with different drug concentrations and without the drug 
as growth control. The ratio of the MIC of the patient isolated to that of H37Rv is 
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calculated after 4 weeks of incubation at 37 ºC, where the MIC is defined here as the 
drug concentration at which the isolate growth has less than 20 colonies. An isolate is 
defined as resistant to the tested drug if its RR is 8 or more, and susceptible if it is 2 or 
less. Despite being the most accurate, RR method is not the most favored on account 
of its labor-intensiveness and cost. However, one advantage of the RR methods is that 
it allows MIC determination.  [24]. 
On the commercial front, several systems are already available and used for 
MTB detection, which provide the facility for high throughput DST of MTB. The 
MGIT 960 system is the only one recommended by the WHO for surveillance of drug 
resistance (first-line drugs) [84], and none of the commercial systems is FDA-
approved for second-line drugs [58]. The automated step in the MGIT 960 is the 
reading of the tubes, while all other preparatory steps are manual. Consequently, the 
main advantage is the reduction in turnaround time to a few days, the overall 
workload is not significantly less than the regular manual method. However, the 
reading throughput is substantially higher [47, 84]. Characteristics of notable 
commercial phenotypic DST systems are presented in table 5. 
 
1.9.1.2. Genotypic DST methods 
Many of the commercial molecular MTB detection systems are also suited, or 
versions of them for resistance detection (table 7), and for in-house assays, similar 
principles are utilized for resistance detection. Commonly, utilized strategies include 
probe hybridization, real-time PCR with hybridization probes, while DNA sequencing 
remains the reference standard. Genotypic methods offer the tremendous advantage of 
bringing down the time for DST to 1-2 days instead of weeks. However, this comes at 
a high monetary cost and with practical reservations [51, 55]. A major issue is the fact 
that the data on resistance–inducing mutations are incomprehensive, and not all 
mutations are translated into phenotypic resistance. Moreover, molecular methods do 
not reflect the proportion of the resistant bacteria in the sample [55]. Additionally, the 
likelihood of false negative results is not to be ignored. This is because absence of a 
mutation does not necessarily mean the isolate is phenotypically susceptible to the 
drug. It is not an uncommon finding that isolates demonstrate phenotypic drug-
resistance while molecular testing shows they lack known resistance-conferring 
mutations [49]. 
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Initially developed over 15 years ago, line probe assays (LPAs) utilize PCR 
amplification with labeled primers, followed by solid phase reverse hybridization. The 
labeled PCR amplicon is incubated in solution on nitrocellulose or nylon membranes 
strips on which target-specific probes are immobilized in parallel lines on solid 
support. Unbound DNA is then washed off, the hybridized probes are visualized by 
color development through enzymatic reaction utilizing the labeled amplicon, 
revealing a pattern of probe hybridization which reflects the resistance status [84-86]. 
There are currently three LPAs on the market; GenoType® MTBDR/MTBDRplus 
and Geno-Type® MTBDRsl (Hain Lifescience, Nehren, Germany) and INNO-LiPA 
Rif.TB (Innogenetics, Zwijndrecht, Belgium) [11, 55]. 
 
One of the main issues with use of molecular assays is the high risk of large 
scale cross contamination, which is why fully automated closed systems are preferred 
despite cost. Additionally, since PCR amplification is an initial step in many 
genotypic assays, presence of polymerase inhibitors is a potential problem [55, 84]. 
However, this was addressed in another successful test which is a hemi-nested real-
time PCR based assay for RIF DST Xpert MTB/RIF (Cepheid Inc., CA, USA) which 
has the advantage of automation and being a closed system, thereby minimizing risk 
of cross contamination. The combination of speed and specificity of LPAs and Xpert 
MTB/RIF assays have led to the WHO recommendation for the expansion for their 
use in screening for drug resistance and initiation of measures to lower cost for 
accessibility by impoverished areas with high burden TB [3, 55, 58, 87]. Both INNO-
LiPA RifTB and Xpert MTB/RIF can detect extrapulmonary TB with high specificity 
(pooled specificity 94% and 96%, respectively), but with limited sensitivity (pooled 
sensitivity 68% and 63%, respectively) [55]. 
 
1.9.2. Emerging DST methods 
About 60% of the global number of TB patients present in remote and peripheral 
healthcare centers lacking the resources and infrastructure for advanced and molecular 
diagnostic systems [88] . Consequently, a number of new techniques have emerged to 
circumvent the disadvantages of high cost and long TAT of conventional culture 
DST, some of which have already gained WHO endorsement.  Other  promising 
approaches are yet to accumulate a sufficient body of supporting evidence e.g. 
mycobacteriophage-based assays, others. The latter include the microscopic 
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observation drug susceptibility (MODS) assay, and the colorimetric assays; the nitrate 
reductase assay (NRA) and the colorimetric redox indicator (CRI) method [32, 84, 
89]. 
 
1.9.2.1. Microcolony growth examination methods 
1.9.2.1.1.  Microscopic observation drug susceptibility assay (MODS) 
The proof-of-concept of MODS as a rapid liquid culture-based method for 
simultaneous detection and DST directly from decontaminated sputum was first 
provided by Caviedes et al. [90], and illustrated the validity of direct detection of 
resistance to RIF and INH with sensitivity of 92% and specificity of 93%. 
Processed sputum samples (or isolate bacterial suspensions) are inoculated 
into supplemented Middlebrook 7H9 broth with and without drugs (INH and RIF) at 
critical concentrations (0.4 and 1 µg/mL, respectively), in 24-well microtiter plates 
(figure 9). The plates are sealed in zip-lock bags and incubated for 7 days at 37 ºC. 
The plates are then microscopically examined for the characteristic cording pattern of 
MTB organisms (figure 10). If no characteristic MTB cords are detected in the drug-
free wells, the reading is repeated every other day up to 21 days, after which the 
sample is declared negative [91-92]. The most recent meta-analysis found MODS to 
have pooled sensitivities of 88.6% and 96.8% for detection of INH and RIF 
resistance, respectively, in direct specimens (n=7), and pooled specificities of 98.5% 
and 99%, with an average TAT of 11.6 days. As for indirect testing the pooled 
sensitivities were 93% and 100% for INH and RIFresistance detection, respectively, 
and the pooled specificities were 100% for both drugs, with an average TAT of 6.5 
days (n=2) [89]. 
The main advantage of MODS is that it utilizes common facilitiesavailable in 
TB laboratories, including those with limited resources, with which the personnel are 
typically familiar. Also, direct DST testing can simply be performed in biosafety level 
2 laboratories and the costly sophisticated level 3 set up is uncalled for. MODS 
combines the relatively rapid growth of culture in liquid media, with a much more 
cost-effective methodology. However, this test method is still fairly labor intensive 
and technically demanding, particularly in inoculation, where contamination risk is 
greatest [32, 47, 49, 82, 84]. Average contamination rate in MODS studies was found 
to be 7.4% [89]. Caution must be exercised when using MODS for direct testing in 
regions with high NTM prevalence as the evidence is still lacking with respect to the 
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assays ability to differentiate them from MTB, particularly M. chelonae. One 
proposed solution for this issue is the inclusion of PNB-containing well which would 
specifically inhibit MTB growth [84, 89]. 
 
1.9.2.1.2. Thin Layer Agar (TLA) Method 
The thin layer agar (TLA) method is also known the microcolony method, and can 
detect mycobacterial growth on agar media within about 10 days. This method uses 
quadrant agar plates with drug-free and drug-containing quadrants (at critical 
concentrations). The quadrants are inoculated with the processed sputum and 
incubated at 37 ºC with 5% CO2. The plate is then examined with a light microscope 
with 100x magnification for colony growth [84, 93-94]. One version of TLA includes 
PNB in one of the quadrants to ensure growth is MTB complex and not an NTM [94]. 
The current body of evidence available for TLA remains insufficient for endorsement 
of its worldwide use [55], where a recent meta-analysis identified only 3 assessment 
studies of TLA, all showing 100% concordance with the reference proportion method. 
Also, a thorough cost analysis is not yet available [89].  
 
1.9.2.2. Colorimetric methods 
1.9.2.2.1.  Colorimetric Redox Indicator (CRI) Assay 
The CRI assay detects the metabolic activity of viable mycobacteria that reduce a 
redox indicator added to the medium after the isolates are incubated with each test 
drug. The reduction causes a change in the color of the indicator, which varies based 
on the used indicator (e.g. Alamar blue or resazurin changes from blue to pink; 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) changes from yellow 
to violet). The metabolic reactions of the viable mycobacteria reduce resazurin (blue) 
to resorufin (pink), while in case of MTT (yellow), it is reduced to insoluble formazan 
(violet), which is then solubilized prior to result reading [79, 95].  
The assay is performed in a microtiter plate, where the isolates to be tested are 
incubated for 7 days at 37ºC with a serial dilution of the drugs in broth, and growth 
and sterility controls are also included. Then the redox indicator is added, the plate 
reincubated, and the plate read the following day (figure 11) [73, 96]. 
The CRI assay was initially developed for screening and evaluation of anti-
tuberculosis drugs and utilized the propriety redox indicator Alamar blue [97] and the 
microplate format was introduced by Franzblau et al. in 1998 [98]. It was later 
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established that Alamar blue and resazurin are basically the same active compound 
(figure 12) and undergo the same reaction in the CRI assay. However, unlike Alamar 
blue, resazurin, usually supplied as a sodium salt, is a non-proprietary reagent [97]. 
Different studies investigated the performance of the CRI assay using MTT, 
Alamar blue, or resazurin, and found them to yield comparable results [79], however, 
there are some factors to be considered in the indicator choice, including reagent 
propriety which affect both cost and access to reagent. As for MTT, the main issue 
associated with its use is the need for an additional solubilization step for 
theformazan, which requires the plate to be opened one more time, thus posing an 
additional risk of assay contamination and biosafety hazard due to possible aerosol 
formation [97]. Moreover, there is a risk of false-resistance results with INH due to its 
potential interference with formazan formation [99]. 
The Alamar blue and resazurin CRI has demonstrated reliable and consistent 
results with regards to INH and RIF susceptibility testing, and subsequently for MDR-
TB detection. However, some discrepancies with regards to MICs were found when 
testing ETH and SM, but had little impact on final designation of sample as resistant 
or susceptible.  The assay can also be carried out using an inoculum from both solid 
and liquid cultures, with no adverse effect on performance [100]. The resazurin-based 
CRI for MDR-TB detection was first introduced by Palomino et al. [96], which is 
now WHO-endorsed and a standardized protocol is now available [64, 101]. An 
evaluation study of the assay in Madagascar yielded sensitivity of 95% for both INH 
and RIF resistance detection, while the specificity was 97.3% for INH and 100% for 
RIF. The total TAT for CRI, including initial isolation was 4-5 weeks versus 7-10 
weeks for LJ-based proportion method [102]. Overall, the reported TATs for these 
assays are much shorter than the 3-6 weeks needed for conventional methods, the 
TATs range between 7-14 days for CRI, exclusive of initial isolation [79]. 
Moreover, a study by Martin et al. [103] incorporated nicotinamide in a 
modified CRI to perform DST for the typically problematic pyrzinamide, on account 
of its requirement for low pH in the media. Additionally, CRI is being evaluated for 
detection of XDR-TB by testing second-line drugs and fluoroquinolones [97, 104]. 
Despite low expectations of success due to high contamination chances, use of direct 
CRI testing on sputum has been attempted using MTT, with promising results, but 
evidence remains too scarce for constructive evaluation [73, 97, 105]. 
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1.8.2.2.2 Nitrate reductase assay (NRA) 
Similar to CRI, the NRA utilizes the biochemical activity of viable Mycobacteria in 
the sample. The basis of NRA is the fact that MTB can reduce nitrate to nitrite, which 
is one of the distinctive biochemical properties of MTB among mycobacteria. This 
ability is lacked by M. bovis, another MTBC member. In this assay the sample is 
incubated with and without the test drug in liquid media containing potassium or 
sodium nitrate at 1000 µg/mL concentration. Resistant strains will remain viable in 
the presence of the drugs, convert the nitrate in the medium to nitrite and result in the 
change of the indicator Griess reagent color to pink. Griess reagent contains an azo 
dye that changes color upon reaction with nitrite in the medium (figure 13).It is 
composed of 50% (v/v) hydrochloric acid, sulfanilamide 0.2% w/v, and N-(1-
naphtyl)ethylene-diamine dihydrochloride 0.1% (w/v) mixed in ratio of 1:2:2. [81, 
106-107].  
NRA can be performed using either solid or liquid media [32, 47, 81, 108], 
and the solid media-based format has been endorsed by the WHO for both direct and 
indirect DST [64]. Direct NRA was found to yield results in median time of 10 days 
(range 10-23 days), and detected MDR-TB with a sensitivity of 97% and specificity 
98% [107]. The indirect LJ-based NRA does not provide significant TAT advantage 
over conventional methods based on use of solid media [47].  
 A few reports illustrate the use of NRA based on liquid media with good 
performance [99, 108-110]. In one approach, the assay was performed using 7H9 
broth with and without INH and RIF at critical concentrations, in screw-cap tubes to 
minimize risk of aerosol formation while benefiting from the high mycobacterial 
recovery rate of liquid media. Despite providing more safety, the use of the liquid-
based NRA in tubes is rather cumbersome and impractical in terms of throughput,  
particularly if MIC determination is to be carried out. Kumar et al. reported the use of 
liquid-based NRA in 96-well microtiter plates [110-111]. Despite safety concerns, this 
format allows handling of smaller culture volumes while allowing for MIC 
determination and increasing throughput as multiple samples can be tested in the same 
plate with multiple drugs. The microplate assay showed 96% concordance with the 
proportion method for detection of INH resistance and 100% for RIF, with results 
available within 8 days [110].  
By detecting the nitrate reduction activity of MTB prior to colony formation, 
NRA offers sensitivity and speed. However, a potential limitation albeit minor, is the 
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assay’s inability to detect the rare nitrate reductase-negative strains of MTB. 
Although, these represent less than 1% of strains, this caveat must always be taken 
into consideration [112]. Another point which must also be considered in use of NRA 
is that Griess reagent cannot detect the reduction of nitrate, beyond nitrite, to nitric 
oxide. The issue is mitigated by addition of a small amount of zinc dust to negative 
tubes, if the nitrate in the medium has already been reduced beyond nitrite, the color 
will not change and the result will be considered a positive. However, if the color 
changes to pink due to rapid reduction of nitrate by zinc, this means it was a true 
negative in the beginning and no nitrate reduction was undertaken by mycobacteria 
[112-113]. The analysis by Martin et al. [81] reported overall TATs of 5 to 12 days 
for indirect NRA, and 14 to 18 days for direct NRA. Direct testing of sputum using 
NRA on liquid media is promising but current data is insufficient for proper 
evaluation [81]. 
 
1.9.2.3. Mycobacteriophage-based assays 
Another promising strategy that is yet to accumulate enough evidence to warrant 
recommendation of large scale or routine use is the mycobacteriophage assay. This 
assay utilizes the natural specificity of certain phage types for infection and 
replication within mycobacteria [24, 55, 65, 84]. 
There are two approaches utilizing mycobacteriophage which were used for 
development of drug resistance detection assays, and a single commercial provider; 
Biotec Labs Ltd, Ipswich, UK. In the first approach, the basis of detection is phage 
amplification, and is the basis of the only commercial phage-based MTB resistance 
detection assay; the CE-marked FASTPlaque assay (Biotec Labs Ltd, Ipswich, UK). 
D29 lytic phage is incubated with the decontaminated sputum samples, with and 
without RIF, and then a virucidal agent is added to eliminate excess phage outside of 
the mycobacterial cells. Progeny phage generation in the viable MTB cells result in 
plaque formation on a lawn of  M. smegmatis (non-pathogenic fast-growing 
mycobacterium) on agar plates, and RIF resistance can thus be detected within 2 days 
[65, 84, 114]. According to the most recent meta-analysis, an average of 21% of direct 
sputum tests using this strategy yielded uninterpretable results. The manufacturer 
introduced the use of an antibiotic supplement containing nystatin, oxacillin and 
aztreonam (NOA). This reduced bacterial and fungal contamination by 68% but 
increased the assay cost. the pooled sensitivity of the direct commercial phage 
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amplification assay was 93.6%, and 95.7% for the indirect assay, and the pooled 
specificities were 96.3% and 94.1%, respectively [114].. The direct assays were 
shown to suffer from unexplained false-resistance results as well as contamination 
problems [84, 114], where.  
The other approach, the luciferase reporter phage assay, is based on using 
bioengineered phages incorporating a luciferase gene, and is used on isolates. These 
phages are incubated with the sample, with and without the drug, and the medium 
contains the substrate luciferin. In viable mycobacteria, the engineered phage is able 
to produce a light signal in presence of luciferin and cellular adenosine triphosphate, 
which can be detected using a luminometer, and a result is obtained within 2 days [65, 
84]. Commercialization of this assay was attempted by Sequella Inc., USA into a 
complete system termed Bronx Box. However, these attempts were recently 
abandoned. The mycobacteriophage assays have demonstrated the advantages of 
rapidity and high sensitivity; however, their drawbacks hinder their practical 
application. At the heart of thesassays are substantial cost elements such as that of the 
engineered phage, the NOA supplement, and the need for a luminometer for signal 
detection (in case of the luciferase assay). Moreover, the time-saving capability of 
direct sputum testing is hindered by siginifcant rates uninterpretable results, and when 
this is combined with the cost factor, the actual practicality of such assays remains 
questionable [30, 114]. 
The above mentioned assays are appropriate examples of approaches that are 
principally sound, but are tackled by the practical and logistical challenges of TB 
detection and resistance testing, including the nature of the primary specimens, and 
slow growing nature of MTB. This is the elusive nature of the balance between 
efficient analytical performance and turnaround time, and cost effectiveness and 
practicality, bearing in mind the financial and logistical settings of the areas and 
markets where TB DST assays are most needed.   
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2.  Project Aims 
1. Evaluation of the performance of the colorimetric redox indicator (CRI) and the 
nitrate reducate assay (NRA) methods for detection of multidrug resistant 
tuberculosis (MDR-TB), defined by resistance to both isoniazid (INH) and 
rifampicin (RIF), in limited resource settings with adequate performance. The 
performance is compared with microscopic observation drug susceptibility assay 
(MODS) and the commercial MGIT 960.  
 
2. PCR amplification and DNA sequencing of part of the 16S rDNA from ten 
random clinical samples being tested using CRI & NRA. This is to confirm that 
the samples’ identities as Mycobacterium tuberculosis (MTB), and to determine if 
there are any strain variations among these Egyptian clinical samples. 
 
3. PCR amplification and DNA sequencing of gene segments containing common 
resistance-conferring mutations, for selected samples. This is to gain insight 
regarding the molecular basis of the detected phenotypic resistance of the samples. 
The target genes are katG and inhA for INH resistance, and rpoB for RIF 
resistance. 
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3. Materials and Methods 
3.1. Samples 
Thirty four mycobacterial isolates on LJ medium, from the sample archive of the 
Naval Medical Research Unit 3 (NAMRU-3) were tested in this study. The samples 
were isolated from sputum samples, collected between 2009 and 2011, from Egyptian 
patients diagnosed with TB, processed using NALC-NaOH method.The samples were 
collected through research project NAMRU3.2010.004: Integration of Microscopic 
Observation Drug Susceptibility (MODS) assay technology into tuberculosis 
surveillance in Egypt between 2009 and 2011, from patients diagnosed with TB. The 
reference strain H37Rv (pathogenic, but sensitive to INH and RIF) was also included. 
The available samples contain 9 drug-resistant isolates, resistant to INH and/or RIF. 
Five isolates were resistant to both RIF and INH and are thus considered as MDR, 3 
isolates were INH-monoresistant, and 1 was RIF-monoresistant. 
 
3.2. Media Preparation 
3.2.1. MODS 
7H9 broth was prepared by weighing 5.9 g Middlebrook broth base powder (BD, NJ, 
USA cat. # 271310), 1.25 g casitone (BD, NJ, USA cat.# 225930) and dissolved in 
900 mL of distilled water, along with 3.1 mL glycerol. The broth was then autoclaved 
and incubated for 24 h at 37°C and checked for sterility (indicated by lack of turbidity 
after incubation). 
 
3.2.2. CRI and NRA 
7H9-supplemented (7H9-S) broth consisting of Middlebrook 7H9 broth, 10% OADC 
supplement (oleic acid, albumin, dextrose, catalase) (BD, USA, cat. #211886), 0.5 % 
glycerol, and 0.1 % casitone was prepared as follows. 0.94 g of 7H9 powder  were 
weighed and dissolved in 180 mL of distilled water, then 0.2 g of casitone were added 
and dissolved. This was followed by addition of 1 mL of glycerol, and the broth was 
autoclaved. After autoclaving and cooling, 20 mL of OADC  were added and mixed 
well. For use in NRA, 1 mL of filter-sterilized NaNO3 (Sigma- Aldrich, cat. # S5022-
1KG) (20% w/v) was added to make 7H9-SN broth. Both media were then incubated 
for 24 h at 37 °C and checked for sterility.  
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3.3. Preparation of Drug Solutions 
3.3.1. MODS 
An INH stock of 8 mg/mL was prepared by dissolving 20 mg INH powder (Sigma-
Aldrich, cat. # 377-50G) in 2.5 mL distilled water. A RIF stock was of 8mg/mL was 
prepared by dissolving 20 mg RIF powder (Sigma-Aldrich, cat. # R3501-5G) in 1.25 
mL dimethyl sulfoxide (DMSO) and then adding 1.25 mL distilled water. Both 
solutions were filtered using 0.2 µm syringe filters (CHM, Spain, cat.# BM316) and 
aliquoted and stored at -20ºC. 
 
3.3.2. CRI and NRA 
An INH stock of 1 mg/mL was prepared by dissolving 2 mg INH powder in 2 mL 
distilled water. A RIF stock of 10 mg/mL was prepared by dissolving 20 mg RIF 
powder in 2 mL absolute methanol. Both solutions were filtered using syringe filters 
and aliquoted and stored at -20ºC. 
 
3.4. Testing of Samples Using MGIT 960 System 
All samples were tested using BACTEC MGIT 960 (BD, NJ, USA), according to 
manufacturer protocol. 
 
3.5. MODS Testing 
The assay was performed as previously described in [91]. 4.5 mL of the prepared 7H9 
broth were placed in sterile screw-cap tubes, and 0.5 mL OADC were added to each 
tube. Several mycobacterial colonies were harvested from LJ slants into sterile screw-
capped tube containing 100 µL of freshly prepared sterile 0.04% Tween 80 (BD, NJ, 
USA, cat # 231181) solution and 4-5 sterile glass beads. The tubes were vortexed for 
2-3 minutes, then allowed to stand for 5 minutes. 3 mL of the Tween 80 solution were 
then added and vortexed again for 20 seconds and the tubes were allowed to stand for 
30 minutes. The supernatant was transferred to another sterile tube and the 
suspension’s turbidity was adjusted to 1.0 McFarland, and 5 µL of each bacterial 
suspension was then added to each supplemented media tube to make up the final 
inoculum. Stock INH and RIF solutions were diluted in broth to working 
concentrations of 4 µg/mL and 10 µg/mL, respectively. 100 µL of the supplemented 
broth were placed in the first two wells of each column of a sterile 24-well microplate 
(BD ,NJ, USA, cat.# 353047), to act as drug-free controls, and 100 µL of each of the 
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working drug solutions were placed in the other two wells 900 µL of the inoculum 
were placed in each of the respective wells of the microplate for each sample. One 
column included only 1 mL broth in all well, with no inoculum to serve as a negative 
control. The plates were then covered with their lids, sealed with autoclave tape, 
placed in ziplock bags, and incubated at 37°C. After incubation for 5 days, the plates 
were then examined under inverted light microscope with 40x magnification (after 
visual examination of wells for turbidity to rule out contamination) to observe the 
characteristic cording pattern of MTB (figure 10). If no cords the plate was 
reincubated and examined again at 7 days, or every two days up to 21 days.  
 
3.6. CRI Testing 
The assay was performed according to the protocol by Martin and Palomino [101]. 
100 µL of 7H9-S broth were placed in each well of a 96-well microplate (Greiner Bio 
One, cat. # 655061), excluding outer perimeter wells. The drug stock solutions were 
diluted in 7H9-S broth to prepare a working INH solution with a 4 µg/mL 
concentration and a RIF solution with an 8 µg/mL concentration. 100 µL of each drug 
working solution were placed in the first row of columns 2-9, then 2-fold serial 
dilutions of the drugs were made down the columns. Inoculums from 21-28 day old 
isolates from LJ cultures were prepared in 7H9-S broth and adjusted to 1.0 McFarland 
standard. The inoculum was diluted 1:20 using 7H9-S broth, and 100 µL of the 
diluted inoculum were used to inoculate the plate (figure 14). Growth control wells 
without drugs for each sample were included as well as sterility control wells with 
only 7H9-S broth, and outer perimeter wells were filled with sterile distilled water. 
The plate was placed in ziplock bag and incubated for 7 days at 37ºC then 30 µL of 
0.01% resazurin solution in distilled water were added to each well and the plate 
sealed and reincubated overnight then read. 
 
3.7. NRA Testing 
The assay was performed based on the method of Kumar et al. [110] with 
modifications. 50 µL of 7H9-SN broth were placed in all wells of a sterile, flat-
bottom 96-well microtiter plate, except column 1 and 12. The drug stock solutions 
were diluted in 7H9-S broth to prepare a working solution of INH (16 µg/mL) and a 
working solution of RIF (32 µg/mL). 50 µL of each working drug solution were 
placed in the first row of columns 2-9, then 2-fold serial dilutions of the drugs were 
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made down the columns. Inoculums from 10-21 day old isolates from LJ cultures 
were prepared in 0.05% Tween 80 in 7H9-S broth and adjusted to 1.0 McFarland 
standard. The inoculum was diluted1:10 in 7H9-SN and the plate was inoculated with 
50 µL of the diluted inoculum in each well (figure 15). Growth control wells without 
drugs for each sample were included as well as sterility control wells with only 7H9-
SN broth and no inoculum. The plate was placed in ziplock bag and incubated for 7 
days at 37ºC then 50 µL of Griess reagent (Sigma-Aldrich, cat. # 03553-100ML) were 
added to each well and the plate sealed and read. 
 
3.8. DNA Extraction 
Extraction  of mycobacterial DNA was performed using a modified enzymatic 
method [115]. The sealed LJ slant tubes containing the bacterial growth were first 
heated in an 80ºC water bath for 1 hr. The bacterial cells were then harvested in 2 mL 
Tris-EDTA (TE) buffer, pH=8, then frozen for 4 hrs, to weaken the cell wall. The 
pellet was then thawed and resuspended in the TE buffer. Delipidation to aid cell 
lysis, was then performed by adding an equal volume of chloroform/methanol mixture 
(2:1) and rocking the tubes for 2 minutes. The suspension was then centrifuged at 
5000 g for 20 minutes, and the bacteria formed a tight band at the interface of the 
aqueous and organic layers, which were discarded and the bacterial band retained. 
The tube containing the bacterial band was heated with the cap opened at 55ºC for 10 
minutes to remove any traces of chloroform, and then the bacterial band was 
resuspeneded in 2 mL TE buffer. 200 µL of Tris-HCl, pH = 9, were then added, 
followed by 10 µL of lysozyme, stock concentration was 10 mg/mL. The tubes were 
then incubated overnight at 37ºC, and then 10 µL of DNAse-free RNAse (Promega, 
cat # M6101), stock concentration 10 mg/mL, were added, and the tubes reincubated 
at 37ºC for 30 minutes. Then a DNA extraction kit (Qiagen, USA, cat.#51304 ) was 
used in accordance with the protocol for gram-positive bacteria after the lysozyme 
digestion step. 
 
3.9. Quantification of extracted MTB DNA 
Concentration of extracted DNA was determined by spectrophotometric measurement 
at 260 and 280 nm using NanoDrop spectrophotometer (Thermo Scientific, USA). 
 
3.10. Sequencing of 16S rDNA 
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3.10.1. Primer design 
A pair of primers targeting a conserved part of the 16S rDNA of Mycobacterium 
genus was designed Vector NTI Advance® v.11.5 (Invitrogen). The conserved region 
was chosen based on multiple sequence alignment analysis against Mycobacterium 
genomes sequences published in NCBI Gene Bank using the same software package. 
 
3.10.2. PCR amplification of 16S rDNA region 
A 514 bp region of the 16S rDNA gene was amplified using standard PCR using our 
designed primers, for 10 randomly chosen isolates from the initial 34 isoaltes . First, 
the extracted MTB DNA was digested using BamHI restriction enzyme (Promega), 
according to manufacturer protocol.  BamHI was selected due to absence of a 
restriction site within the target region. Dimethylsulfoxide (Sigma-Aldrich, 
cat.#276855) was added in the master mix (Promega, USA, cat.#M7142), at 5% final 
concentration, and the mix was used for PCR. A 50 µL PCR reaction was prepared by 
mixing 25 µL PCR Master Mix 2X, 2.5 µLof 10 µM of each of the forward and 
reverse primers, 5 µL of DNA template, and 15 µL nuclease-free water. PCR was 
done in 25 cycles: initial denaturation at 95°C for 2 min, denaturation at 95°C for 30  
s, annealing  at 61°C for 1 min, extension at 72°C for 45 s, and final extension at 72°C 
for 2 min in a thermal cycler (Veriti, Applied Biosystems CA, USA). Amplification 
was verified by electrophoresis of the amplicon on 2% agarose gel and visualization 
of the ~500 bp band using ethidium bromide staining. A 100 bp ladder (Promega, 
USA, cat.#G2101) was used for band size comparison. 
 
3.10.3. DNA sequencing of 16S rDNA 
The same primers that were used for PCR amplification of the 16S rDNA region were 
used for sequencing (forward and reverse) the amplicon using ABI 3730xl DNA 
sequencer  (Applied Biosystems, CA, USA) according to manufacturer’s protocols. 
 
3.10.4. 16S DNA sequence data analysis 
Vector NTI 11.5 software was used to assemble, trim, and then align all sequencing 
results along with the full 16S sequence of the reference strains H37Rv (GenBank no. 
X52917.1), and they were also analyzed using NCBI Blast for alignment against 
available DNA sequences in the NCBI database. 
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3.11. Sequencing of INH and RIF resistance-related genes 
3.11.1. Primer design 
Two pairs of primers were obtained from the literature to target katG [116] , and rpoB 
[117] genes, while another pair targeting inhA regulatory region was designed using 
the Vector NTI 11.5 software (table 9).  
 
3.11.2. PCR amplification of resistance-related regions of katG, inhA, and rpoB 
The target regions of katG, rpoB, and the regulatory region of inhA of 3 
phenotypically drug resistant samples, 3 phenotypically susceptible samples, and the 
reference drug-susceptible strains H37Ra, were amplified by conventional PCR. First, 
the extracted MTB DNA was digested using EcoRI restriction enzyme (Promega, 
USA, cat# R4014), according to manufacturer protocol.  EcoRI was selected due to 
absence of a restriction site within the target region. Dimethylsulfoxide 
(DMSO),(Sigma-Aldrich, cat. #276855) was added in the master mix (Promega, 
USA, cat.# M7142), to yield final concentration of 5%, and the mix was then used for 
PCR. A 50 µL PCR reaction was prepared by mixing 25 µL PCR Master Mix 2X, 2.5 
µL of 10 µM of each of the forward and reverse primers, 5 µL of DNA template, and 
15 µL nuclease-free water. PCR was done in 25 cycles: initial denaturation at 95°C 
for 2 min, denaturation at 95°C for 30 s, annealing  for 1 min (temperature used for 
each primer is listed in table 9), extension at 72°C for 45 s, and final extension at 
72°C for 2 min in a thermal cycler (Veriti, Applied Biosystems CA, USA). 
Amplification was verified by electrophoresis of the amplicon on 2% agarose gel and 
visualization of the bands using ethidium bromide with comparison to a 100 bp ladder 
(Promega, USA, cat.#G2101). 
 
3.11.3. DNA sequencing of katG, inhA, and rpoB 
The same primers that were used for PCR amplification of the inhA, katG and rpoB 
regions were used for sequencing (forward and reverse) the amplicon using ABI 
3730xl DNA sequencer  (Applied Biosystems, CA, USA) according to manufacturer 
protocols. 
 
3.11.4. DNA sequence data analysis for katG, inhA, and rpoB 
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Vector NTI 11.5 software package was used to assemble, trim, and then align all 
sequencing results along with the full sequence of the reference strain H37Ra, and 
they were also analyzed using NCBI Blast. 
 
3.12. Biosafety measures 
 All steps for preparation of MODS, CRI, and NRA were performed in a level 2 
biosafety cabinet (BSC-2), with the operator wearing N-95 mask. For plate reading 
and documentation, the plates were always maintained in the sealed ziplock bags, and 
the N-95 mask was always on when the plates were removed from the BSC to be 
examined under the microscope (in case of MODS) or examined using the plate 
mirror and photographed. As for the DNA extraction process, the heat 
decontamination, and harvesting the cells into the TE lysis buffer steps are performed 
inside the BSC while wearing the N-95 mask. The remaining steps were performed 
outside the BSC with common level 2 laboratory safety precautions. 
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4. Results 
4.1. Samples 
Thirty four mycobacterial isolates, comprising the sample pool were characterized 
using both MODS and MGIT, with complete concordance between both methods 
(table 10). Five samples were found to be MDR, 3 monoresistant to INH, 1 
monoresistant to RIF, and 25 were sensitive to both drugs.  The MGIT testing was 
performed on the standard panel of first-line drugs SM, INH, RIF, ETH (SIRE panel). 
6 isolates also demonstrated resistance to SM and 2 to ETH. One sample was only 
included in the molecular studies and not in the culture-based resistance detection 
using CRI and NRA, for safety reasons, as MGIT results indicated its resistance to all 
4 drugs in the SIRE panel. 
 
4.2. Phenotypic detection of drug resistance 
4.2.1. Colorimetric redox indicator assay (CRI) 
CRI assay was performed on 31 isolates; 4 isolates were MDR, 3 monoresistant to 
INH, 1 monoresistant to RIF, 23 sensitive to both drugs. The MICs of the resistant 
isolates ranged from 0.125 to  > 1 µg/mL for INH, and from 0.5 to >2 µg/mL for RIF, 
and thus one isolate which was INH monoresistant by MGIT and MODS was found 
sensitive by CRI. Concordance was 96.7% with MGIT and MODS reference methods, 
and assay reproducibility was established by random repeat testing of isolates. 
Performance of CRI is presented in table 11. An example of a CRI plate result is 
shown in figure 16. 
 
4.2.2.   Nitrate reductase assay (NRA) 
NRA was performed on 30 isolates, 4 MDR, 3 monoresistant to INH, 1 monoresistant 
to RIF, and 22 sensitive to both drugs. The MICs of the resistant isolates were 
determined, The MICs of the resistant isolates ranged from 5 to > 8 µg/mL for INH, 
and from 10 to >16 µg/mL for RIF. Concordance was 93.3% with MGIT and MODS, 
and false resistance to RIF was obtained for one INH monoresistant isolate, and 
another INH resistant isolate yielded a false sensitive result for INH. Assay 
reproducibility was demonstrated by random repeat testing of isolates. Performance of 
NRA is presented in table 12. An example of an NRA plate result is shown in figure 
17. 
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4.2.3. Turnaround times (TAT) 
CRI median TAT was 8 days (range 7 to 10 days), and that of NRA was 7 days (range 
6 to 8 days). MGIT TAT ranged from 5 to 13 days, and MODS from 7 to 21 days.  
 
4.2.4. Age of tested isolates in CRI and NRA 
Since both CRI and NRA are indirect testing methods, that require initial bacterial 
isolation, the age of isolates affected the TAT. Optimum age of isolates testing was 
determined to be 18-29 days for CRI, and 13-21 days for NRA, which yielded clearest 
and most consistent results. Although, valid CRI result were obtained for isolates 
ranging in age from 12-32 days, and 12-28 days for NRA (one MDR isolate 32 days 
old yielded valid results). 
 
4.2.5. Cost analysis 
The cost of both assays was estimated with respect to used media, drugs, indicator, 
and microplates and other consumables. The cost of testing an isolate for resistance to 
both INH and RIF using CRI and NRA was found to be $4.5 and $5.2, respectively. 
 
4.3.  PCR amplification and sequencing of 16S rDNA 
4.3.1. Selection of PCR primers 
The target region for the designed primers was chosen to be a highly conserved part 
of the 16S rDNA of Mycobacterium genus, as multiple alignment analysis against 
Mycobacterium genomes sequences, including the reference strain H37Rv published 
in NCBI Gene Bank showed high degrees of homology (figure 18). 
 
4.3.2.  PCR amplification of 16S rDNA region 
A clear band of ~500 bp size was visualized on agarose gel electrophoresis thus 
supporting amplification of the target region (figure 19). 
 
4.3.3. DNA sequencing 
The PCR amplicons for the 16S rDNA were sequenced and the sequencing results 
showed clear sharp bands and low background noise (figure 20). 
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4.3.4. Blast analysis 
Blast analysis of sequencing results for 16S rDNA (forward and reverse sequences 
assembled) using NCBI nucleotide Blast software yielded results supporting sample 
identities as Mycobacterium tuberculosis (figure 21). E-value was 0.0 indicating the 
high significance of the obtained results. Alignment of the sequences and construction 
of the relationship dendrogram showed that all the samples clustered closely except 
for two samples (#321 and #361), which clustered together differently (figures 22 and 
23).  
 
4.3.5. Mutation analysis 
The amplified part of 16S rDNA encompasses the rrs gene, which is known to harbor 
point mutations correlated with resistance to SM. The sample sequences and that of 
the reference H37Rv (GenBank no. X52917.1) were aligned using AlignX Vector 
NTI 11.5.  Analysis of the sequences’ alignment for polymorphisms showed two point 
mutations at nucleotide 513 (AT) and 526 (CT) based on E. coli numbering 
system, in two samples known to be SM-resistance by MGIT analysis (figure 24). 
 
4.4.  PCR amplification and sequencing of inhA, katG and rpoB regions 
4.4.1. Selection of PCR primers 
All primers for katG, inhA, and rpoB were verified for specificity by multiple 
alignment analysis against Mycobacterium genomes sequences published in NCBI 
Gene Bank using the Vector NTI 11.5 software package. 
 
4.4.2.  PCR amplification of inhA, katG and rpoB regions 
A clear band of ~400 bp size for katG amplicon, and at ~600 bp size for inhA and 
rpoB amplicons were visualized using agarose gel electrophoresis thus supporting 
amplification of the target regions. 
 
4.4.3. DNA sequencing 
The PCR amplicons for the inhA, katG and rpoB genes were sequenced and the 
sequencing results showed clear sharp peaks and low background noise. 
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4.4.4. Mutation analysis 
The katG sequences obtained from the isolates, and the sequence of the reference 
strain and that of the full gene for the reference H37Ra (GenBank accession # NC_ 
009525) were aligned using AlignX Vector NTI 11.5. The process was repeated with 
the rpoB sequences. Analysis of the sequences’ alignment for polymorphisms showed 
a point mutations in the katG sequences of samples #314 and #344, both MDR, in 
codon 315. As for rpoB, a point mutation in codon 526 in sample #344 (MDR), and 
another mutation in codon 531 in sample #314, which is also MDR. No mutations 
were found in the inhA regulatory region. The observed mutations and corresponding 
amino acid changes are listed in table 13. Figures 25 and 26 present the sequence 
alignments showing the described mutations. 
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5. Discussion 
5.1. Evaluation of colorimetric DST assays CRI and NRA 
The regular challenge facing DST for MTB infection is striking the balance between 
cost and speed while maintaining accuracy. The most rapid direct molecular methods 
are very costly and require high expertise, and even the slower automated culture 
systems are also expensive with high infrastructure and maintenance requirements.  
The more affordable conventional culture methods have a very long TAT, this is on 
top of the specific technical challenges of each individual assay. The aim of this study 
was to evaluate the performance of two colorimetric liquid culture-based assays that 
could fit the requirements for TB DST in the regions where resources are limited, and 
especially where MDR-TB is a particular issue.  
A selection of 34 mycobacterial isolates grown on LJ media from processed 
sputum obtained from Egyptian TB patients, was characterized using for growth and 
DST using the in-house method MODS and the commercial liquid culture system 
MGIT 960. Both MODS and CRI are in-house methods endorsed by the WHO for 
DST, while the microplate format used in this study has not been sufficiently 
investigated. 
The primary point of strength in MODS is its suitability for use for direct 
sputum testing, which is a significant advantage for speeding up reporting of results. 
However, this comes at the cost of increased contamination risk, as is the case with 
most direct DST approaches. Additionally, the need for inverted microscopes (cost 
about $1000[49], and are not part of standard laboratory setting), highly trained 
personnel for result determination, which is also highly subjective, weigh up to the 
cons of this rapid method. 
  
CRI and NRA results were 96.7% and 93.3% concordant with those of MGIT 
and MODS and, two of the validly tested samples were smear-negative. The 
performance of CRI is more established by virtue of the existing body of literature 
although more large scale studies in the target populations are needed. As for the 
presented NRA format, there is limited data, and further testing is warranted by the 
potential advantages. These include high specificity to MTB, shorter overall 
turnaround time, and immediate result generation after indicator addition. The use of a 
liquid-media based approach would positively affect TAT and ease of performance, as 
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solid media for use in NRA have to be prepared in-house. Although this is a process 
typically familiar to laboratory staff in limited-resource areas, which also may have a 
cost advantage over buying ready commercial reagent, this is a lengthy labor-
intensive procedure, and reproducibility of batches would be a concern. Additionally, 
there is an uncertainty regarding actual drug potency when incorporated in LJ media, 
particularly that loss of potency may occur due to the high temperature used during 
inssipation [11, 110]. Actually, this one reason why the egg-based LJ medium is not 
regarded as suitable for DST, along with possible interference of its components with 
drug activity. Even for the reference proportion method, OADC-supplemented 
Middlebrook 7H10 agar is recommended medium by the CDC and CLSI [11]. A 
collateral advantage is the fact that the indicator Griess reagent kills the mycobacteria 
[11], thus reducing biohazard risk during documentation and disposal, albeit this does 
not indicate any change in the standard biosafety measures. Despite the availability of 
a tube version of NRA utilizing liquid culture, we opted for the optimization of a 
microplate format. This allows handling of smaller culture volumes while allowing 
for MIC determination and increasing throughput as multiple samples can be tested in 
the same plate, which is more manageable and easier to handle in the restricted space 
of a biosafety cabinet. Both assays utilize non-propriety reagents, and do not require 
any specialized or costly equipment. This is an important advantage for areas with 
low infrastructure and unstable power supply where sophisticated equipment like the 
MGIT 960 system cannot be reliably maintained. Table 14 compares the cost and 
infrastructure requirements for the 4 methods used in this study. 
The evaluated colorimetric assays fit in between the performance of 
conventional solid culture-based DST and the sophisticated cutting edge molecular 
assays, with regards to cost, simplicity, and turnaround time. At the same time, they 
offer reliable DST results. Capacity building for TB-afflicted regions, especially 
HBCs would require substantial time and resources to reach up to the recommended 
and desired DST, and is also affected by multiple factors beyond the medical scope 
e.g. political and economic environment. Therefore, CRI and NRA are suitable tools 
for the interim phase, as supported by WHO endorsement. 
Establishment of breakpoint concentrations that reflect clinically significant 
drug resistance is an important process, yet it is no simple feat and requires MICs 
distribution analysis of the target population [37, 118]. Thus, a point that must be 
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noted with regards to results interpretation is the fact that the used protocol for CRI 
breakpoint concentration to designation of an isolate as drug resistant were  ≥0.25 
µg/mL for INH, and ≥0.5 µg/mL for INH, which was also used to NRA. However, 
this was established based on testing of the study population. One isolate (#361) 
showed a clear degree of resistance by CRI with MIC of 0.125 µg/mL, which is below 
the standard break point. However, given that all drug-sensitive isolates did not 
demonstrate any mycobacterial growth under the same assay conditions. Although 
this isolate had to be considered to have a discordant result by CRI and NRA under 
the used cutoffs, it may actually be considered to be intermediately resistant. Such a 
determination and it clinical relevance is to be assessed by a larger scale study on the 
Egyptian population. 
 
5.2. Molecular characterization of clinical isolates 
Multiple alignment using Align X of the Vector NTI 11.5 software package of the 
sequenced 16S rDNA revealed polymorphisms at positions 513, and 526 of rrs were 
found in three samples, two of which have been found to be SM resistant by MGIT. 
Mutations at these locations, in general the region around nucleotide 530 (table 4), 
(clinical frequency 2% for position 526) have been shown to be correlated with 
resistance to SM, and degree of resistance may also be relevant [119-122]. Samples 
#314 and #321 are streptomycin resistant according to MGIT results from NAMRU-3, 
however, no data on MIC are available. Therefore exact correlation with MIC cannot 
be determined, although current information in the literature correlates rrs with low to 
moderate resistance [21, 123]. Mutations related to SM resistance in the rrs gene (16S 
rDNA) are actively being studied in the current literature. 
 On the resistance front, the two MDR sample for which katG and rpoB were 
sequenced demonstrated common high-confidence resistance-conferring mutations, 
none of which were observed in the drug-susceptible strains. The observed mutations 
are consistent with those commonly described in the literature (table 4). Also, they 
are consistent with those which were found to be of highest frequency in studies 
performed on Egyptian samples [124-125]. As for the INH monoresistant sample 
#361, the lack of mutations in either katG or inhA, combined with the observed 
discrepancy between its MGIT and MODS results and those of CRI and NRA, may 
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suggest either the presence of mutations in other uncommon genes  or that there is a 
different origin of the phenotypic resistance such as an efflux mechanism.  
Finally, on a general note, one of the important, yet underestimated, factors to 
consider in method evaluation is the prior familiarity of the person performing the 
evaluation of the method.  Higher performance indicators are typically reported when 
the method is evaluated by its industry or original developer, and about 40% of 
studies on diagnostics of TB, HIV, and malaria encompass industry association of 
some sort [114]. This creates a hidden bias, and in this study, the fact that the operator 
had no prior familiarity with TB DST, or the tested methods, offers a fairly true 
assessment of their degree of applicability and trainability in new settings. 
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6. Conclusions and Future Perspectives 
This study has evaluated the performance of low-cost rapid TB DST colorimetric 
methods; CRI and NRA in Egypt, a moderate-resource setting. Both assays 
demonstrated highly concordant results with reference methods and rapid TAT. Also, 
their cost estimates (exclusive of labor and overheads) are around $5 (for testing an 
isolate for 2 drugs with MIC determination) (table 14) versus MGIT cost per test $32-
56 (test only at critical drug concentrations) [49]. It is also to be noted that the cost of 
NRA can be further reduced by preparing the Griess reagent in-house as opposed to 
using a readymade commercial preparation as was done in this study. This 
performance indicates suitability for use in reference laboratories with limited 
resources, without the need for extensive staff training or equipment. Additionally, 
result documentation is much simpler when compared to MODS. 
 The evaluated assays, CRI and NRA, provide low cost, relatively low 
complexity, rapid indirect phenotypic DST. These assays are best suited for use in 
central laboratories in resource poor areas with high TB prevalence. The use of 
colorimetric detection adds to saving in both number and training of laboratory 
personnel. Reading simplicity would increase number of sample reads per technician, 
who also require only basic training, as opposed to MODS which requires specially 
trained personnel for cording pattern detection and plate reading. Also, subjectivity in 
result reading is minimized in color-based detection, which would only pose a 
problem in case of the reading being performed by color-blind individual [83]. 
Another advantage of these colorimetric assays is the possibility of 
quantification of mycobacterial load, as the indicator color is reflective of the amount 
of viable mycobacteria [97]. This can be done either spectrophotometrically, or more 
simply by computer analysis of the image taken of the plate. Considering that both 
indicators; resazurin and Griess reagent, yield a degree of pink color, the image can be 
analyzed for RGB content using any of the basic image editing software, freely 
available on computer. A simple basic computer code can also be specially designed. 
This is an upgrade of the assays that is to be pursued. 
The primary limitation of this study is the number of samples and expansion 
of this study to include a larger number of Egyptian patients is warranted. Also, a 
larger proportion of the samples is to be MDR so as to further explore he prevailing 
resistance-conferring mutations. The mutations are to be correlated with the 
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subsequent degree of phenotypic resistance, which would aid disease detection and 
control efforts. This is taking into consideration the possibility of MTB strain 
heterogeneity in Egypt, indicated by the two clustering patterns obtained from the 
analysis of the 16S rDNA of 10 out of the 34 samples (figure 22). The lack of data on 
Egyptian strains, except an unexpected high proportion of Manu lineage [43], warrant 
such an investigation. Additionally, for proper large scale implementation of CRI and 
NRA and accurate clinically relevant interpretation of their results, MICs for resistant 
Egyptian isolates are to be analyzed. They are then to be used to verify whether the 
currently used breakpoint concentrations are suitable for the target population or if 
their modification is warranted. 
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7. Tables 
Table 1. Egypt TB statistics.  [3, 126] 
Parameter Number/Percentage Year 
Incidence 18 per 100,000, estimated total of 
15,000 cases 
2010 
Prevalence 28 per 100,000, estimated total of 
23,000 cases 
2010 
Mortality less than 1 per 100,000, estimated 
660 cases 
2010 
Case detection rate 64% 2010 
% of MDR-TB in new cases 2.2% 2010 
% of MDR-TB in retreatment 
cases 
38% 2010 
Estimated cure rate (among 
new smear-positive pulmonary 
cases) 
72% 2009 
% of notified new TB cases 
tested for MDR: 
1% 2009 
Total number of confirmed 
MDR-TB  among new and 
retreatment patients 
204 2009 
Number of smear laboratories 0.4 per100,000 population 2010 
Number of DST laboratories less than 0.1 per 5 million population 2010 
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Table 2. Definitions of key terms related to drug resistance of tuberculosis. 
Term Definition Reference(s) 
Primary drug  
resistance 
Resistance to a drug which is detected in an 
isolate from a patient who has not previously 
received, or has received less than one month  of 
drug therapy 
[24, 127] 
Acquired drug 
resistance 
Resistance to a drug which is detected in an 
isolate obtained from a patient actively 
undertaking antimyobacterial therapy or has 
previously been treated. 
[21, 24] 
Multi-drug 
resistance 
(MDR) 
Resistance of an isolate to both RIF and INH [24, 30] 
Drug-resistant 
isolate 
An isolate is generally considered resistant to a 
given drug if more than 1% of the bacteria 
exhibit resistance to that drug (applies to the 
majority of anti-TB drugs). 
[24] 
Minimum 
inhibitory 
concentration 
(MIC) 
The first concentration of the drug that prevents 
isolate’s growth and change of indicator color. 
[101] 
Critical 
concentration 
A single concentration calibrated as midway 
between the highest and lowest MICs of 
different wild type strains, which is defined as 
the concentration which kills 95% or more of the 
wild type bacteria, not previously exposed to a 
drug. It is used as a cut off in qualitative drug 
susceptibility assays.  
[24, 123] 
Direct DST DST performed on primary clinical specimens 
without prior bacterial culturing. 
[58] 
Indirect DST DST performed on pure isolates cultured from 
primary clinical specimens 
[58] 
DST: drug susceptibility testing; INH: isoniazid; MIC: minimum inhibitory 
concentration; RIF: rifampicin; TB: tuberculosis 
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Table 3. Main first-line TB drugs, mode of action, biochemical description, and resistance conferring mutations [21, 25-26, 46]. 
Drug Description Mode of Action Administration 
Method 
Utility in Treatment Main Possible Adverse 
Effects 
Molecular 
Basis of 
Resistance 
Isoniazid 
(INH) 
Isonicotinylhydrazine, 
a prodrug which is 
transformed to the 
active form by the 
catalase peroxidase 
enzyme of the 
bacteria 
Interferes with the 
enzymatic synthesis of 
mycolic acid. 
Mainly oral, but in the 
critically ill, it may be 
injected 
intramuscularly or 
intravenously. 
Bactericidal affecting 
actively replicating 
bacilli only. 
- Systemic or 
cutanous 
hypersensitvity early 
in treatment. 
- Lethargy 
- Neuropathy 
Mutations in 
inhA, katG 
Rifampicin 
(RIF) 
A macrocyclic lipid-
soluble antibiotic 
which is a 
semisynthetic 
raifamycin derivative. 
Disruption of DNA 
synthesis, by binding to 
the  subunit of the 
RNA polymerase. 
Oral, and possibly 
intravenous for the 
critically ill. 
Bactericidal, affects 
both replicating 
bacteria and those 
with low metabolic 
rates. Both 
intracellular and 
extracellular bacilli 
are potently sterilized 
by RIF. 
- Gastrointesitnal 
reactions. 
- Pruritus without 
rash. 
- Exfoliative 
dermatitis is more 
often encountered 
with HIV patients. 
Mutations in 
rpoB 
Ethambutol 
(ETH) 
[(2S,2’S)-2,2’-
(ethylenediimino)-
1,2-diyldiimino)di-1-
butanol],  
 
Interferes with 
biosynthesis of the 
MTB cell wall 
components 
arabinogalactan, and 
lipoarabinomannan.  
Oral. Bacteriostatic agent 
effective only on 
actively growing 
bacilli. It is used with 
other first-line TB 
drugs to delay 
emergence of 
resistance. 
- Dose-dependent 
optic neuritis, 
normall reversible. 
- Occasional 
peripheral neuritis in 
legs. 
Mutations in 
embB 
Streptomycin Aminoglycoside Interferes with mRNA Deep intramuscular Killing actively - Injections are Mutations in 
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(SM) antibiotic translation by binding to 
the 30S ribosomal 
subunit and the thus 
inhibits bacterial protein 
synthesis. 
injection. Also, 
available for 
intravenous injection. 
replicating bacteria, 
but has no effect on 
intracellular and non-
replicating bacteria  
painful, and rash or 
sterile abscesses may 
appear at the 
injection site. 
- Numbness around 
the mouth right after 
the injection. 
- Possible cutaneous 
hypersensitivity. 
- Nephrotoxicity 
rpsL and rrs 
Pyrazinamide 
(PZA) 
Synthetic 
nicotinamide 
analogue, which is a 
prodrug converted by 
MTB to the active 
compound 
pyarazinoic acid. 
Disrupts membrane 
potential of MTB and 
causes cytoplasmic 
acidification by drawing 
in protons.  
Oral. Potent sterilization 
activity aimed 
particularly at 
intracellular bacilli in 
the low pH 
environment with 
macrophages. It is 
also weakly 
bactericidal. Its 
sterilizing effects 
allow shortening of 
treatment duration. 
- Gastrointestinal 
reactions. 
- A degree of hyper 
uricemia. 
- Hepatotoxicity. 
Mutations in 
pncA 
 
 
  
47 
 
Table 4. Molecular basis of resistance to first-line anti-TB drugs [21, 119-120, 123, 128]. 
 
Drug Most Commonly 
Mutated Gene(s) 
in Resistant 
Strains (mutation 
target region) 
Normal Gene 
Product/role 
Relative 
Frequency in 
Resistant Strains 
Typical 
Association with 
Phenotypic 
Resistance 
Typical MICs 
(Test Media) 
Common High 
Confidence 
Mutations 
Mutation 
Frequency 
Isoniazid 
(INH) 
inhA 
(regulatory region) 
Enoyl-acyl carrier 
protein reductase 
6-30% Moderate to 
high level 
resistance 
>1 mg/L Nucleotide (-)15 6-30% 
katG 
(entire gene) 
Catalase/peroxidase 50-95% Low level 
resistance 
0.02–0.2  
mg/L(7H9/7H10) 
Codon 315  
50-95% 
Rifampicin 
(RIF) 
rpoB 
(81 bp hotspot 
region) 
-subunit of RNA 
polymerase 
90-95% Dependant on 
specific 
mutation, but 
mostly high 
level resistance 
0.05–0.1 mg/L 
(7H9/7H10) 
Codon 
516,Codon 531 
(Ser531Leu, His 
526Tyr, 
His526Asp) 
30-75% 
(54%, 11%, 
7%) 
Ethambutol 
(ETH) 
embB 
(many codons) 
Arabinosyltransferase 47-89% Low to moderate 
level resistance 
1–5  mg/L 
(7H9/7H10) 
Codon 306 20-70% 
Streptomycin 
(SM) 
rpsL 
(codons 43 and 
48) 
Ribosomal protein 
S12 
 
40-95% 
High level 
resistance 
2–8  mg/L 
(7H9/7H10) 
rpsL 42 Arg, rpsL 
42 Thr, rpsL  42 
Asn 
88%, <1%, 
<1% 
Rrs 16S rRNA N/A Moderate level 
resistance 
N/A rrs 523 C, rrs 522 
T, rrs 526 T 
6%, 3%, 2% 
Pyrazinamide 
(PZA) 
pncA 
(many codons) 
Pyrazinamidase 
responsible for 
conversion of the 
prodrug to active 
form 
62-97% Mostly high 
level resistance 
16–50 mg/L (LJ)  
N/A 
 
N/A 
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Table 5. Main diagnostic strategies for TB infection. 
Test Detected marker Advantages Limitations Reference(s) 
Smear examination TB bacilli - Simple. 
- Cheap. 
- Good specificity, particularly in TB 
endemic areas. 
- Variable sensitivity (20-80%). 
- Not very useful in patients with low 
sputum bacillary load e.g. children and 
HIV patients. 
- Highly dependent on skill of smear 
examiner. 
[3, 11, 30, 129] 
Tuberculin skin test Antibody response to 
TB proteins 
- Simple. 
- Cheap. 
- Suitable for detection of latent 
infection. 
- Variable specificity. 
- Can give false positive results with 
vaccinated individuals or previous 
exposure. 
[2-3] 
Interferon--release 
assays 
Cellular immune 
response to  TB 
infection 
- Limited infrastructure and 
equipment required. 
- Moderate personnel training needed. 
- Good specificity to MTB. 
- Useful for use with BCG-vaccinated 
individuals. 
- Ineffective in case of severely 
immunocompromised individuals or the 
very young. 
[2-3, 58] 
Liquid and solid culture TB bacterial growth  - High specificity. 
- Can be adapted for determination of 
drug sensitivity. 
- Complex. 
- High personnel training required. 
- Costly infrastructure and consumables 
required. 
[3] 
Nucleic acid tests (e.g. 
PCR, real-time PCR, 
SDA, LAMP, LPAs) 
TB bacterial DNA - High specificity and sensitivity. 
- Fast. 
- Decreased contamination risk in 
case of real-time PCR. 
- High equipment and consumables cost. 
- Extensive staff training and expertise 
needed 
[3, 30, 130] 
BCG: Bacillus Calmette–Guérin; LAMP: loop-mediated isothermal amplification; LPAs: line probe assays; PCR: polymerase chain reaction, SDA: strand 
displacement amplification 
 
  
49 
 
Table 6. Performance parameters for notable commercial phenotypic DST systems 
System Media Basis of growth detection DST (Drugs) DST TAT References 
Bactec 460  
(BD Diagnostic 
Systems, MD, 
USA) 
Middlebrook 
7H12 broth 
Detection of mycobacteria growth by detecting 
14
CO2 liberated by actively growing bacteria from 
14
C-labeled palmitic acid in the modified 
MiddleBrook 7H12 broth 
First-line 9.3 days [24] 
Bactec MGIT 
960 
(BD Diagnostic 
Systems, MD, 
USA) 
Middlebrook 
7H9 broth 
An oxygen-quenched fluorophore (tris 4, 7-
diphenyl-1, 10-phenonthroline ruthenium chloride 
pentahydrate,) is embedded in the bottom of the 
culture tube. As the bacteria grows and the oxygen 
is consumed the fluorescence signal increases. The 
automated system reads out the tubes 
automatically, while in the manual version the 
tubes are scanned using a UV light and positive 
growth is indicated by orange fluorescence. In 
DST fluorescence in the drug containing tubes is 
compared with that of the drug-free growth tube to 
determine positive growth and thus resistance in 
the drug tube. 
First-line. Some 
studies also 
indicate possible 
use with ofloxacin 
and kanamycin 
- DST TAT:  5-14 days after 
primary isolation, where TAT 
for TB detection is 4-13 days. 
 
- A sample is declared negative 
after 42 days of no growth. 
 
[47, 49, 
131] 
BacT/Alert MB 
(bioMeriuex, NC, 
USA) 
Modified 
Middlebrook 
7H9 broth 
A colorimetric sensor is incorporated in the 
medium which measures the production of carbon 
dioxide by the growing mycobacteria, and growth 
is indicated by change in color of indicator from 
green to yellow. 
First-line  6-8 days [24, 65] 
VersaTrek (Trek 
Diagnostic 
Systems, OH, 
USA) [formerly 
known as the ESP 
Culture System II] 
Enriched 
Middlebrook 
7H9 broth 
The system monitors pressure changes in the 
headspace of the culture vial, generated by the 
mycobacterial metabolic activity. 
First-line  4-8 days [65, 132] 
 FDA approved. DST: drug sensitivity testing; TAT: turnaround time.  
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Table 7.  Commercial molecular assays for MTB detection and drug susceptibility testing. 
Assay Samples Assay principle Target Analytical Performance References 
 COBAS® Amplicor® 
MTB Test 
(Roche Diagnostics, 
Switzerland) 
Pulmonary 
specimens 
PCR amplification of 584 bp fragment of 16S 
rRNA gene. the biotin labeled amplicon is then 
hybridized to MTBC specific probes coated to 
microtiter plate, followed by colorimetric 
detection.  
16S rDNA   Smear-positive samples: 
Sensitivity: 97% 
Specificity:>95%  
 Smear-negative  samples: 
Sensitivity: 40-73% 
Specificity:>95% 
 TAT: 6.5 hrs 
[51, 68, 
133] 
COBAS® TaqMan® MTB 
Test  
(Roche Diagnostics, 
Switzerland) 
Pulmonary 
specimens 
Real-time PCR reaction for the amplification 
of genus specific region of 16S rRNA gene. 
The amplicon is detected by genus specific 
Taqman® probes  
16S rDNA   Smear-positive samples: 
Sensitivity: 96.9 % 
Specificity:100% 
 Smear-negative samples: 
Sensitivity: 79.5 % 
Specificity: 98.7 % 
 TAT: 2.5 hrs after sample preparation 
[133] 
 AMPLIFIED MTD 
(Mycobacterium 
Tuberculosis Direct) Test 
(Gen-Probe,, CA, USA) 
Pulmonary 
specimens 
The test qualitatively detect MTBC rRNA by 
utilizing Transcription-Mediated Amplification 
(TMA) for amplification of genus specific 16S 
rRNA target and Hybridization Protection 
Assay (HPA) for chemiluminescent detection 
of amplified targets. 
16S rDNA  Smear-positive samples: 
Sensitivity: 92-100% 
Specificity:>95% 
 Smear-negative  samples: 
Sensitivity: 40-93% 
Specificity:>95% 
 TAT: 2.5 to 3.5 hrs 
[51, 134-
135] 
 AccuProbe 
MYCOBACTERIUM 
Culture Identification Test 
(Gen-Probe, CA, USA) 
Cultured 
isolates 
The test utilize nucleic acid hybridization 
technique and HPA for the identification of 
Mycobacterium isolated from cultures 
16S rDNA  Sensitivity: 99.2% 
 Specificity: 99.9% 
 TAT: 2-3 hrs after growth of isolates 
[136-137] 
INNO-LiPA 
MYCOBACTERIA v2 
(Innogenetics, Ghent, 
Belgium) 
Solid and 
early Liquid 
culture 
A  reverse hybridization assay. First 
biotinylated primers are used to amplify 16-
23S spacer region. The biotinylated amplicon 
is then hybridized with specific 
oligonucleotide probes immobilized on 
membrane based strips in parallel lines. 
16S-23S rDNA spacer 
region 
 Sensitivity: 100% 
 Specificity: 94.4% 
 
[51, 138] 
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Following hybridization color is developed 
using alkaline phosphatase labeled streptavidin 
and the substrate to develop purple/brown 
color at positive bands. 
INNO-LiPA Rif.TB 
(Innogenetics, Gent, 
Belgium) 
Solid and 
early liquid 
culture 
The test principle is the Same as INNO-LiPA 
MYCOBACTERIA v2.  
rpoB   Smear-positive samples: 
Pooled sensitivity: 93% 
Pooled specificity: 83% (reports range from 80 to 
100%) 
 Smear-negative samples: 
Pooled sensitivity: 65% 
Pooled specificity: 96%  
 TAT: <2 hrs 
 Estimated cost per test $15-45 
[49, 51, 
55, 139] 
GenoType® MTBC 
(Hain Lifescience, Nehren, 
Germany) 
Culture  Amplification of RNA isolated from sample 
by) technique (NASBA). Finally the amplified 
product is hybridized membrane based strip in 
a reverse hybridization approach 
23S rRNA  Sensitivity: 92% 
 Specificity: 100% 
 TAT: 5 hrs 
[49, 68] 
GenoType MTBDRplus  
(Hain Lifescience, Nehren, 
Germany) 
Sputum or 
culture  
The test include three steps, DNA extraction 
from clinical specimen or cultured material 
(solid or Liquid) followed by multiplexed 
amplification with biotinylated primers. The 
biotin labeled amplicons are then hybridized to 
membrane bound probes. 
rpoB 
katG 
inhA 
 MTBC detection 
Sensitivity: 94.4% 
 RIF resistance 
Sensitivity: 96.2% 
Specificity: 90.2% 
 INH resistance 
Sensitivity: 97.3% 
Specificity: 83.3% 
 TAT: 1-2 days 
 Estimated cost per test $15-45 
[49, 52, 
68, 139-
140] 
Xpert MTB/RIF 
(Cepheid Inc., CA, USA) 
Sputum Automated real-time PCR targeting specific 
resistance related regions. 
rpoB  Smear-positive samples: 
Pooled sensitivity: 98% 
Pooled specificity: 99% 
 Smear-negative samples: 
Pooled sensitivity: 75% 
Pooled Specificity: 99%  
 
 TAT: 6-48 hours 
[49, 55] 
 FDA approved. HPA: Hybridization protection assay; INH: isoniazid; NASBA: Nucleic Acid Sequence Based Amplification; RIF: rifampicin. 
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Table 8.  Comparison of different non-commercial phenotypic drug susceptibility assays for M. tuberculosis. 
Assay Medium Sample TAT/Cost Advantages Limitations References 
Slide DST Liquid Sputum 
10 days 
- Simplicity. 
- Safety  
- Valid only for 
sputum positive 
cases. 
- No available 
controls.  
[65, 84] 
Thin layer agar Middlebrook 
7H10 or 7H11 
agar 
Pulmonary and 
extrapulmonary  
specimens 
13 days 
- Simple requirements of 
agar and conventional light 
microscope. 
 
-  A CO2 incubator is 
required. 
[55, 65, 
84, 94] 
E-Test Agar  Isolate 
 
5-10 days 
- Rapid resistance detection 
within 5-10 days. 
- MIC determination. 
- Requires very high 
inoculum 
concentration 
[65] 
MODS* Middlebrook 
7H9 broth 
Sputum or 
isolates 
- TAT: 7-9 days 
- Cost per 
test $1.3 to 3.5 
- Speed and possible direct 
detection. 
- Low cost 
- Special personnel 
training needed. 
- Highly subjective 
to readers’ skills. 
- False-resistance 
chances are high 
due to 
misidentification of 
artifacts as TB 
cords. 
[49, 65, 
141] 
CRI (using 
resazurin 
indicator)* 
Middlebrook 
7H9 broth 
Isolates - TAT: 8 days. 
- Pooled 
sensitivity 
97% for INH, 
and 98% for 
RIF. 
- Pooled 
specificity 
98% for INH, 
99% for RIF. 
- Demonstrated 
suitability for 
- MIC determination. 
- Sample throughput is high. 
- Simple reading and 
interpretation. 
- Biosafety concern 
over repeated 
opening of the 
culture plate. 
[47, 64, 
79, 97, 
142] 
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both first and 
second-line 
drugs. 
- Cost $3.75 per 
sample per 
drug 
NRA* - LJ 
 
Sputum or 
isolates 
Combined for 
direct and indirect 
testing: 
- Sensitivity 
97%  for both 
INH and RIF 
resistance 
- Specificity 
99% for INH 
and 100% for 
RIF resistance 
- Cost $3-4 
- Direct rapid testing. 
- Ease of result reading  
- Possible false-
susceptibility 
results with rare 
nitrate reductase-
negative strains. 
 
[49, 64] 
- Middlebrook 
7H9 broth 
Sputum or 
isolates 
Direct Testing: 
- Sensitivity 
100% for both 
INH and RIF 
- Specificity 
99.2% INH 
and 99.3% for 
RIF 
- Cost about 
$3.7 per 
isolate for 
indirect test at 
critical drug 
concentration. 
- MIC determination with 
increased throughput. 
- Ease of result reading. 
- MTB specificity. 
- Possible false-
susceptibility 
results with rare 
nitrate reductase-
negative strains. 
 
[81, 108-
109] 
*Assay sensitivity and specificity for MODS, CRI, and LJ-based NRA are based on WHO multicenter studies [64]. 
CRI: colorimetric redox indicator assay; INH: isoniazid; MODS: microscopic observation drug susceptbility; NRA: nitrate reductase assay; 
RIF: rifampicin; TAT: turnaround time 
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Table 9. PCR primers used for amplification of resistance-related genes. 
Gene Forward Primer Reverse Primer Annealing 
Temp. 
(°C) 
Amplicon 
Length 
(bp) 
Reference 
inhA TCCACACCCTGCGGCA
CGTA 
TGGCGTTGATGACCTT
CTCG 
51 590 --- 
katG TTGACCTCCCACCCGA
CTTG  
AGCTCGTATGGCACC
GGAAC 
51 620 
 
[116] 
 
rpoB CAGACCACGATGACCG
TTCC 
GAGCCGATCAGACCG
ATGTT 
50 443 [117] 
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Table 10. Samples results by MODS and MGIT. 
Resistance pattern No. of Samples 
INH monoresistant 3 
RIF monoresistant 1 
MDR (INH + RIF resistant) 5 
Sensitive 25 
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Table 11. CRI clinical performance (N=31) 
Drug Sensitive Resistant Sensitivity Specificity PPV NPV 
Isoniazid  24/24 6/7 100% 96% 85.7% 100% 
Rifampicin 26/26 5/5 100% 100% 100% 100% 
Both drugs 
(MDR) 
23/23 4/4 100% 100% 100% 100% 
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Table 12. NRA clinical performance (N=30). 
 
Resistance type Sensitive Resistant Sensitivity Specificity PPV NPV 
Isoniazid  23/23 6/7 85.7% 100% 100% 95.8% 
Rifampicin 24/25 5/5 100% 96% 83.3% 100% 
Both drugs (MDR) 22/22 4/4 100% 100% 100% 100% 
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Table 13.Mutations observed in the sequenced resistance-related gene region of isolates demonstrating phenotypic resistance. 
Sample # Phenotypic Resistance Gene 
Observed Mutation 
(Amino Acid Change) 
Position 
314 
INH 
RIF 
SM 
ETH 
inhA 
--- 
--- 
katG AGCACC 
(Ser  Thr) 
Codon 315 
rpoB TCGTTG (Ser Leu) Codon 531 
344 
INH 
RIF 
inhA --- 
 
--- 
katG AGCACC 
(Ser  Thr) 
Codon 315 
rpoB CACTAC (HisTyr) Codon 526 
361 INH 
inhA 
--- 
---- 
rpoB ---- ---- 
katG ---- ---- 
ETH: ethambutol; INH: isoniazid; RIF: rifampicin; SM: streptomycin; wt: wild type 
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Table 14. Comparison between the cost and  infrastructure requirements of MGIT, MODS, CRI, and NRA [65, 87]. 
 MGIT MODS CRI NRA 
Special equipment 
needed 
Yes Yes No No 
Propriety reagents Yes No No No 
Operator training 
requirements 
Moderate High Low  Low 
DST Cost per isolate for 
both RIF and INH 
$32-56 [49] $1.4-3.5[49] $4.5 (this study) $5.2 (this study) 
Laboratory 
infrastructure 
Advanced Regular Regular Regular 
Throughput Very high (up to 960 
samples per run) 
Moderate High  High 
MIC determination No No Yes Yes 
CRI: colorimetric redox indicator assay; DST: drug susceptibility testing; INH: isoniazid; MGIT: Mycobacterial Growth Indicator 
Tube; MIC: minimum inhibitory concentration; MODS: microscopic observation drug susceptbility; NRA: nitrate reductase assay; 
RIF: rifampicin. 
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8. Figures 
 
 
 
Figure 1. Estimated worldwide TB incidence rates in 2010. Reprinted from [3]. 
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Figure 2. Structure of mycobacterial cell wall. Reprinted from [143].  
The exceptional high content of mycolic acid and peptidoglycan in the cell wall is the origin of the acid-fastness property of MTB. 
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Figure 3. Global distribution of percentage of MDR-TB cases among newly notified TB cases. Reprinted from [34]. 
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Figure 4. M. tuberculosis evolutionary scenario and geographical spread.“The main migrations events are numbered and 
correspond to: 1, M. prototuberculosis, the ancestor of the MTBC, this bacterium reached the Fertile Crescent some 40,000 years ago 
by sea or land; 2 and 3, two distinct basal lineages arose, EAI and LAM and spread out of Mesopotamia some 10, 000 years ago;  4, 5 
and 6, later on (8–5000 years ago) derived populations from clade 1 followed main human migration patterns to Africa, Asia and 
Europe, giving rise to locally adapted tubercle strains and further diversifications” Reprinted from [40]. 
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Figure 5. Chemical structures of first-line anti-TB drugs. A) Rifampicin, B) Isoniazid, C) Streptomycin, D) Ethambutol, E) 
Pyrazinamide. Reprinted from [144]. 
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Figure 6.  Action of different drugs in treatment of TB infection. Each drug targets the bacteria at a different metabolic states, to 
ensure killing of all bacteria in the body. Reprinted from [48]. 
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Figure 7. Acid-fast staining of MTB bacilli in sputum (x1000 magnification) [12].
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Figure 8. Colonies of MTB on LJ medium [145].
1 
 
 
 
Figure 9. MODS plate layout. The samples are incubated with 7H9-supplemented broth in 24-well microplates. For each sample two 
well contain each of the drugs at critical concentration and the other two do not and act as growth control. The plate is then sealed and 
incubated at 37º C for a week and then examined under an inverted microscope. Reprinted from [92]. 
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Figure 10. Characteristic cord-like appearance of MTB under the microscope in 
MODS (20x). Reprinted from [146]. 
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Figure 11. CRI overview. Samples are incubated in broth with a serial dilution o f the 
drugs in 96-well microtiter plate. The plate is then incubated for 7-10 days at 37 ºC, and 
then a redox indicator is added e.g. resazurin or 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). The plate is then reincubated overnight and then the 
plate is observed for color change of the indicator reflecting bacterial growth.  Successful 
bacterial growth in drug-containing wells indicates bacterial resistance to that drug. 
Reprinted from [79]. 
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Figure 12. Chemical structure of resazurin.  
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Figure 13. Reaction of Griess indicator used in nitrate reductase assay. A 
diazotization reaction is employed in the assay where sulphanilic acid reacts with nitrite 
to form a diazonium salt intermediate, which then reacts with N-(1-
naphthyl)ethylenediamine to form the pink azo dye. The color formation indicates the 
presence of viable bacteria converting the nitrate in the media to nitrite, where the latter 
reacts with the Griess reagent to form the colored product [147]. 
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Figure 14. CRI plate layout. Two columns are dedicated to each sample, and each  
column contains a serial dilution of each drug (I  isoniazid, R rifampicin). Blank (B) 
controls containing only media are included for sterility check, and duplicate growth 
controls (GC) are also included for each sample and contain only the sample and media 
without drugs. 
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Figure 15. NRA plate layout. Two columns are dedicated to each sample, and each  
column contains a serial dilution of each drug (I  isoniazid, R rifampicin). Blank (B) 
controls containing only media are included for sterility check, and duplicate growth 
controls (GC) are also included for each sample and contain only the sample and media 
without drugs.  
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Figure 16.Typical CRI plate result. Mycobacterial growth is detected by change of 
indicator color from blue to pink. GC is the growth control. Results of this plate are: 
sample 410 is sensitive to both drugs, sample 428 is resistant to both drugs (MDR), 
sample 326 is sensitive to both drugs, and sample 331 is sensitive to both drugs.  
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Figure 17.Example of NRA plate result. Mycobacterial growth is detected by change of 
indicator color from very faint pink to deep or reddish pink. GC is thegrowth control. 
Results of this plate are: 6 is RIF-resistant, H37Rv is sensitive to both drugs. Sample 428 
and 430 failed to show growth in the control wells .  These samples were retested.  
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Figure 18. Alignment results for forward (A) and reverse (B) primers for 
amplification of 16S rDNA region using Vector NTI 11.5 software. 
The alignment shows the high degree of conservation of the chosen region throughout 
Mycobacterium genomes. 
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Figure 19. Agarose gel electrophoresis  result for the 16S rDNA amplion. The band 
at~500 bp matches the expected amplicon size. 
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Figure 20. Part of the16S rDNA sequencing result for sample #314. The peaks are 
clear and sharp peaks and background noise is low. 
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Figure 21.  Blast analysis results for sample #314. This confirms sample identity as 
Mycobacterium tuberculosis. 
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Figure 22. Alignment of 16S rDNA sequences. The alignment shows high homology 
between 8 out of the 10 sample while the remaining two are partially homologous. 
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Figure 23.  Dendrogram for relationship between samples based on 16S sequencing. 
Two samples clustered away from the remaining samples indicating possible strain 
difference. 
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Figure 24. Alignment 16S rDNA for samples demonstrating phenotypic resistance to 
streptomycin. Two samples show mutations at positions 513 and 526 (E. coli 
numbering). 
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Figure 25. Alignemnt of katG sequences with marked mutations in codon 315. These 
marked mutations are known to confer resistance to INH and the two samples in which 
they were detected are phenotypically MDR, resistant to both INH and RIF. 
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Figure 26. Alignment of rpoB sequences with marked mutations in codons 526 and 
531(E. coli numbering). These marked mutations are known to confer resistance to RIF 
and the two samples in which they were detected are phenotypically MDR, resistant to 
both INH and RIF. 
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